<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combined inhaled anticholinergics and short‐acting beta2‐agonists for initial treatment of acute asthma in children - Griffiths, B - 2013 | Cochrane Library</title> <meta content="Combined inhaled anticholinergics and short‐acting beta2‐agonists for initial treatment of acute asthma in children - Griffiths, B - 2013 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000060.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combined inhaled anticholinergics and short‐acting beta2‐agonists for initial treatment of acute asthma in children - Griffiths, B - 2013 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000060.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD000060.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Combined inhaled anticholinergics and short‐acting beta&lt;sub&gt;2&lt;/sub&gt;‐agonists for initial treatment of acute asthma in children" name="citation_title"/> <meta content="Benedict Griffiths" name="citation_author"/> <meta content="St Thomas' Hospital" name="citation_author_institution"/> <meta content="bgriffiths@doctors.org.uk" name="citation_author_email"/> <meta content="Francine M Ducharme" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="8" name="citation_issue"/> <meta content="10.1002/14651858.CD000060.pub2" name="citation_doi"/> <meta content="2013" name="citation_date"/> <meta content="2013/08/21" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000060.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000060.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD000060.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Inhalation; Adrenergic beta‐2 Receptor Agonists [administration &amp; dosage, *therapeutic use]; Asthma [*drug therapy]; Atropine [administration &amp; dosage, therapeutic use]; Cholinergic Antagonists [administration &amp; dosage, *therapeutic use]; Disease Progression; Drug Therapy, Combination [methods]; Hospitalization [statistics &amp; numerical data]; Ipratropium [administration &amp; dosage, therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD000060.pub2&amp;doi=10.1002/14651858.CD000060.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="4nUWI3Cc";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD000060\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD000060\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","fr","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD000060.pub2",title:"Combined inhaled anticholinergics and short\\u2010acting beta\u003csub\u003e2\u003c/sub\u003e\\u2010agonists for initial treatment of acute asthma in children",firstPublishedDate:"Aug 21, 2013 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Airways Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000060.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000060.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD000060.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD000060.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000060.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD000060.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD000060.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD000060.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD000060.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD000060.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>5170 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD000060.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-sec-0090"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-sec-0022"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-sec-0023"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-sec-0027"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-sec-0028"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-sec-0050"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-sec-0077"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/appendices#CD000060-sec-0095"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/table_n/CD000060StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/table_n/CD000060StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2013 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combined inhaled anticholinergics and short‐acting beta<sub>2</sub>‐agonists for initial treatment of acute asthma in children </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/information#CD000060-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Benedict Griffiths</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD000060.pub2/information#CD000060-cr-0003">Francine M Ducharme</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/information/en#CD000060-sec-0101">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 21 August 2013 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD000060.pub2">https://doi.org/10.1002/14651858.CD000060.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD000060-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000060-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000060-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000060-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000060-abs-0002">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD000060-abs-0001" lang="en"> <section id="CD000060-sec-0001"> <h3 class="title" id="CD000060-sec-0001">Background</h3> <p>There are several treatment options for managing acute asthma exacerbations (sustained worsening of symptoms that do not subside with regular treatment and require a change in management). Guidelines advocate the use of inhaled short acting beta<sub>2</sub>‐agonists (SABAs) in children experiencing an asthma exacerbation. Anticholinergic agents, such as ipratropium bromide and atropine sulfate, have a slower onset of action and weaker bronchodilating effect, but may specifically relieve cholinergic bronchomotor tone and decrease mucosal edema and secretions. Therefore, the combination of inhaled anticholinergics with SABAs may yield enhanced and prolonged bronchodilation. </p> </section> <section id="CD000060-sec-0002"> <h3 class="title" id="CD000060-sec-0002">Objectives</h3> <p>To determine whether the addition of inhaled anticholinergics to SABAs provides clinical improvement and affects the incidence of adverse effects in children with acute asthma exacerbations. </p> </section> <section id="CD000060-sec-0003"> <h3 class="title" id="CD000060-sec-0003">Search methods</h3> <p>We searched MEDLINE (1966 to April 2000), EMBASE (1980 to April 2000), CINAHL (1982 to April 2000) and reference lists of studies of previous versions of this review. We also contacted drug manufacturers and trialists. For the 2012 review update, we undertook an 'all years' search of the Cochrane Airways Group's register on the 18 April 2012. </p> </section> <section id="CD000060-sec-0004"> <h3 class="title" id="CD000060-sec-0004">Selection criteria</h3> <p>Randomized parallel trials comparing the combination of inhaled anticholinergics and SABAs with SABAs alone in children (aged 18 months to 18 years) with an acute asthma exacerbation. </p> </section> <section id="CD000060-sec-0005"> <h3 class="title" id="CD000060-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed trial quality and extracted data. We used the GRADE rating system to assess the quality of evidence for our primary outcome (hospital admission). </p> </section> <section id="CD000060-sec-0006"> <h3 class="title" id="CD000060-sec-0006">Main results</h3> <p>Twenty trials met the review eligibility criteria, generated 24 study comparisons and comprised 2697 randomised children aged one to 18 years, presenting predominantly with moderate or severe exacerbations. Most studies involved both preschool‐aged children and school‐aged children; three studies also included a small proportion of infants less than 18 months of age. Nine trials (45%) were at a low risk of bias. Most trials used a fixed‐dose protocol of three doses of 250 mcg or two doses of 500 mcg of nebulized ipratropium bromide in combination with a SABA over 30 to 90 minutes while three trials used a single dose and two used a flexible‐dose protocol according to the need for SABA. </p> <p>The addition of an anticholinergic to a SABA significantly reduced the risk of hospital admission (risk ratio (RR) 0.73; 95% confidence interval (CI) 0.63 to 0.85; 15 studies, 2497 children, high‐quality evidence). In the group receiving only SABAs, 23 out of 100 children with acute asthma were admitted to hospital compared with 17 (95% CI 15 to 20) out of 100 children treated with SABAs plus anticholinergics. This represents an overall number needed to treat for an additional beneficial outcome (NNTB) of 16 (95% CI 12 to 29). </p> <p>Trends towards a greater effect with increased treatment intensity and with increased asthma severity were observed, but did not reach statistical significance. There was no effect modification due to concomitant use of oral corticosteroids and the effect of age could not be explored. However, exclusion of the one trial that included infants (&lt; 18 months) and contributed data to the main outcome, did not affect the results. Statistically significant group differences favoring anticholinergic use were observed for lung function, clinical score at 120 minutes, oxygen saturation at 60 minutes, and the need for repeat use of bronchodilators prior to discharge from the emergency department. No significant group difference was seen in relapse rates. </p> <p>Fewer children treated with anticholinergics plus SABA reported nausea and tremor compared with SABA alone; no significant group difference was observed for vomiting. </p> </section> <section id="CD000060-sec-0007"> <h3 class="title" id="CD000060-sec-0007">Authors' conclusions</h3> <p>Children with an asthma exacerbation experience a lower risk of admission to hospital if they are treated with the combination of inhaled SABAs plus anticholinergic versus SABA alone. They also experience a greater improvement in lung function and less risk of nausea and tremor. Within this group, the findings suggested, but did not prove, the possibility of an effect modification, where intensity of anticholinergic treatment and asthma severity, could be associated with greater benefit. </p> <p>Further research is required to identify the characteristics of children that may benefit from anticholinergic use (e.g. age and asthma severity including mild exacerbation and impending respiratory failure) and the treatment modalities (dose, intensity, and duration) associated with most benefit from anticholinergic use better. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD000060-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD000060-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD000060-abs-0007">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD000060-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD000060-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ru#CD000060-abs-0005">Русский</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD000060-abs-0004" lang="en"> <h3>Combined inhaled anticholinergics and beta2‐agonists for initial treatment of acute asthma in children </h3> <p><b>Background</b> <br/> In an asthma attack, the airways (small tubes in the lungs) narrow because of inflammation (swelling), muscle spasms and mucus secretions. Other symptoms include wheezing, coughing and chest tightness. This makes breathing difficult. Reliever inhalers typically contain short‐acting beta<sub>2</sub>‐agonists (SABAs) that relax the muscles in the airways, opening the airways so that breathing is easier. Anticholinergic drugs work by opening the airways and decreasing mucus secretions.<br/> <br/> <b>Review question</b> <br/> We looked at randomised controlled trials to find out whether giving inhaled anticholinergics plus SABAs (instead of SABAs on their own) in the emergency department provides benefits or harms in children having an asthma attack.<br/> <br/> <b>Key results</b> <br/> We found that children with a moderate or severe asthma attack who were given both drugs in the emergency department were less likely to be admitted to the hospital than those who only had SABAs. In the group receiving only SABAs, on average 23 out of 100 children with acute asthma were admitted to hospital compared with an average of 17 (95% CI 15 to 20) out of 100 children treated with SABAs plus anticholinergics. Taking both drugs was also better at improving lung function. Taking both drugs did not seem to reduce the possibility of another asthma attack. Fewer children treated with anticholinergics reported nausea and tremor, but no significant group difference was observed for vomiting.<br/> <br/> <b>Quality of the evidence and further research</b> <br/> Most of the studies were in preschool‐ and school‐aged children; three studies also included a small proportion of infants under 18 months of age, although there was no evidence that inclusion of these infants with wheezy episodes affected the results. Nine trials (45%) were at a low risk of bias and we regarded the evidence for hospitalisation as high quality. Physicians can administer the dose of anticholinergic and SABA in several different ways; as a single dose, or as a certain number of doses or more flexibly. Most of the trials gave the children two or three doses and we think that more research is needed to improve characterization of children that benefit from, and the most effective number and frequency of doses of, anticholinergic treatment. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD000060-sec-0090" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD000060-sec-0090"></div> <h3 class="title" id="CD000060-sec-0091">Implications for practice</h3> <section id="CD000060-sec-0091"> <p>The findings of this Cochrane review support the use of anticholinergics in addition to SABAs over SABAs alone in the management of acute asthma in children, with an anticipated 27% reduction in the risk of hospital admission. The absence of statistically significant subgroup difference in treatment response between severity subgroups or those receiving different treatment intensity (multiple fixed‐dose versus single‐dose) prevents firm conclusions regarding a possible effect modification associated with treatment intensity and asthma severity. Yet, given the large weight of the trials pertaining to children with moderate or severe asthma (with an under‐representation of those with mild asthma) and the absence of effect in the mildest subgroup, it seems prudent to recommend the systematic use of anticholinergics in children with moderate or severe asthma only. Similarly, as most of the evidence is derived from trials testing a multiple fixed‐dose protocol using three doses of 250 mcg or two doses of 500 mcg of ipratropium bromide administered by nebulizer over 60 to 90 minutes, in combination with a SABA, we would recommend this treatment strategy and duration. There are also insufficient data to comment on the efficacy of adding anticholinergic to every SABA treatment, that is, titrating the number of both therapies to the child's response, on the optimal duration of combination therapy, and no evidence to explore whether the anticholinergic dose should be adjusted to the child's age. The addition of anticholinergics to SABAs was associated with significantly less tremor and nausea than SABAs alone. </p> </section> <h3 class="title" id="CD000060-sec-0092">Implications for research</h3> <section id="CD000060-sec-0092"> <p>Future trials should be designed to address five issues, the impact on the magnitude of effect of: (1) the severity of airway obstruction (mild asthma and impending respiratory failure); (2) child's age (preschooler‐aged versus school‐aged children); (3) intensity/flexibility of therapy (fixed versus flexible); (4) dose of anticholinergics (250 mcg versus 500 mcg) and (5) delivery devices (nebulization versus inhalation). This could be done by conducting head‐to head comparisons with different doses, treatment intensity (multiple fixed‐dose versus multiple flexible‐dose protocols) and different inhalation modalities (metered dose inhaler versus nebulization) or by stratifying on child's age and baseline severity or both. Indeed, future research must attempt to define the severity of asthma exacerbation reliably and reproducibly in the study population by standardized methods (e.g. spirometry, respiratory resistance or interrupter technique) or validated clinical scores, or both. Any such attempts should consider the difficulties of using spirometric parameters in a young population (<a href="./references#CD000060-bbs2-0058" title="AretsH , BrackelH , Van derEntC . Forced expiratory manoeuvres in children: do they meet ATS and ERS criteria for spirometry?. European Respiratory Journal2001;18:655‐60. ">Arets 2001</a>), although it offers the most objective means to ascertain the severity of airway obstruction reliably (<a href="./references#CD000060-bbs2-0079" title="SilvermanRA , FlasterE , EnrightPL , SimonsonSG . FEV1 performance among patients with acute asthma: results from a multicenter clinical trial. Chest2007;131(1):164‐71. ">Silverman 2007</a>). Alternate measures include use of clinical scores with validated cut‐offs for severity such as the Pediatric Respiratory Assessment Measure (<a href="./references#CD000060-bbs2-0060" title="ChalutDS , DucharmeFM , DavisGM . The Preschool Respiratory Assessment Measure (PRAM): a responsive index of acute asthma severity. Journal of Pediatrics2000;137(6):762‐8. ">Chalut 2000</a>; <a href="./references#CD000060-bbs2-0063" title="DucharmeFM , ChalutD , PlotnickL , SavadieC , KudrikaD , ZhangXun , et al. The Pediatric Respiratory Assessment Measure: a valid clinical score for assessing acute asthma severity from toddlers to teenagers. Journal of Pediatrics2008;152(4):476‐80. ">Ducharme 2008</a>). </p> <p>Because systemic glucocorticoids are now the standard treatment of children with moderate and severe exacerbations, they should be systematically given with SABAs in future trials. Trials are needed to examine the effect of adding anticholinergics in a multiple flexible‐dose manner, that is, each time a SABA is deemed necessary. </p> <p>Future trials should include more sensitive and reliable endpoints such as number of bronchodilator inhalations and oxygenation (during the emergency department treatment), duration of hospitalisation and duration of need for intensive (at less than four‐hour interval) bronchodilator inhalation (for hospitalised children) and attempt to measure time to full recovery in discharged participants, that is, the duration of symptoms, rescue SABA use, functional status and quality of life. </p> <p>In addition, it seems urgent to assess the efficacy and duration of anticholinergics in children with impending respiratory failure at risk of admission or admitted to the intensive care unit. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD000060-sec-0022" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD000060-sec-0022"></div> <div class="table" id="CD000060-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anticholinergic and short‐acting beta2‐agonists versus beta2‐agonists alone (all protocols) for initial treatment of acute asthma in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anticholinergic and shorth‐acting beta<sub>2</sub>‐agonists (SABA) versus SABA alone (all protocols) for initial treatment of acute asthma in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with initial treatment of acute asthma<br/> <b>Settings:</b> emergency department<br/> <b>Intervention:</b> anticholinergic and SABA versus SABA alone (all protocols) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Anticholinergic and SABA versus SABA alone (all protocols)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcome: hospital admissions</b> <br/> hospital admissions </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 100</b> <br/> (15 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.73</b> <br/> (0.63 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2497<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies had no admissions so did not contribute to the RR.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SABA:</b> short‐acting beta‐agonists. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD000060-sec-0023" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD000060-sec-0023"></div> <section id="CD000060-sec-0024"> <h3 class="title" id="CD000060-sec-0024">Description of the condition</h3> <p>Asthma is caused by inflammation in the airways and bronchoconstriction, which makes it difficult to breathe and leads to wheezing and breathlessness. The underlying inflammation causes the lining of the airways to secrete mucus, which also obstructs the free flow of air through the lungs. The bronchoconstriction is alleviated by using bronchodilators such as short acting beta<sub>2</sub>‐agonists (SABAs), while the underlying inflammation can be treated with regular inhaled corticosteroids. However, symptoms may flare up in response to an asthma trigger (e.g. virus, dust, pollen) leading to an asthma exacerbation. It is not known why the inflammation, secretions and bronchoconstriction occur. Asthma exacerbations can be life threatening and may require more medications than are used on a day‐to‐day basis. </p> </section> <section id="CD000060-sec-0025"> <h3 class="title" id="CD000060-sec-0025">Description of the intervention</h3> <p>The initial management of acute paediatric asthma exacerbations in children focuses on the rapid relief of bronchospasm using inhaled or nebulized bronchodilators (<a href="./references#CD000060-bbs2-0059" title="British Thoracic Society and Scottish intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline, 2011. www.brit‐thoracic.org.uk/guidelines (accessed 8 August 2013). ">BTS 2011</a>; <a href="./references#CD000060-bbs2-0064" title="Global INitiative forAsthma . Global strategy for asthma management and prevention, 2011. www.ginasthma.org (accessed 8 August 2013). ">GINA 2011</a>). Children who do have moderate or severe asthma and those who do not respond sufficiently to bronchodilators to relieve symptoms require the addition of oral or intravenous glucocorticoids (<a href="./references#CD000060-bbs2-0059" title="British Thoracic Society and Scottish intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline, 2011. www.brit‐thoracic.org.uk/guidelines (accessed 8 August 2013). ">BTS 2011</a>; <a href="./references#CD000060-bbs2-0064" title="Global INitiative forAsthma . Global strategy for asthma management and prevention, 2011. www.ginasthma.org (accessed 8 August 2013). ">GINA 2011</a>; <a href="./references#CD000060-bbs2-0070" title="LougheedMD , LemiereC , DucharmeFM , LicskaiC , DellSD , RoweBH , et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Canadian Respiratory Journal2012; Vol. 19, issue 2:127‐64. [1916‐7245: (Electronic)] ">Lougheed 2012</a>). SABAs are clearly the most effective bronchodilators due to their rapid onset of action and the magnitude of achieved bronchodilation (<a href="./references#CD000060-bbs2-0077" title="SearsMR . Clinical application of beta‐agonists. Practical Allergy and Immunology1992;7:98‐100. ">Sears 1992</a>; <a href="./references#CD000060-bbs2-0080" title="SvedmyrN . A beta2‐adrenergic agonist for use in asthma pharmacology, pharmacokinetics, clinical efficacy and adverse effects. Pharmacotherapy1985;5:109‐26. ">Svedmyr 1985</a>; <a href="./references#CD000060-bbs2-0081" title="TeohL , CatesC , HurwitzM , AcworthJP , VanAsperenP , ChangAB . Anticholinergic therapy for acute asthma in children. Cochrane Database of Systematic Reviews2012, Issue 4. [DOI: 10.1002/14651858.CD003797.pub2] ">Teoh 2012</a>). Anticholinergic agents, such as ipratropium bromide and atropine sulfate, have a slower onset of action and weaker bronchodilating effect, but may specifically relieve cholinergic bronchomotor tone and decrease mucosal edema and secretions (<a href="./references#CD000060-bbs2-0061" title="ChapmanK . An international perspective on anticholinergic therapy. American Journal of Medicine1996;100:2‐4S. ">Chapman 1996</a>; <a href="./references#CD000060-bbs2-0066" title="GrossNJ . Ipratropium bromide. New England Journal of Medicine1988;8:486‐94. ">Gross 1988</a>; <a href="./references#CD000060-bbs2-0078" title="SilvermanM . The role of anticholinergic antimuscarinic bronchodilator therapy in children. Lung1990;168:304‐9. ">Silverman 1990</a>). Thus, the combination of inhaled anticholinergics with SABAs may yield enhanced and prolonged bronchodilation. </p> <p>National and international guidelines recommend the addition of anticholinergics to inhaled SABAs in people with an acute severe asthma exacerbation and suggest consideration of this therapy in people with moderate exacerbations (<a href="./references#CD000060-bbs2-0059" title="British Thoracic Society and Scottish intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline, 2011. www.brit‐thoracic.org.uk/guidelines (accessed 8 August 2013). ">BTS 2011</a>; <a href="./references#CD000060-bbs2-0064" title="Global INitiative forAsthma . Global strategy for asthma management and prevention, 2011. www.ginasthma.org (accessed 8 August 2013). ">GINA 2011</a>). </p> </section> <section id="CD000060-sec-0026"> <h3 class="title" id="CD000060-sec-0026">Why it is important to do this review</h3> <p>The first version of this Cochrane review published in 1997 found a significant reduction in hospital admissions in school‐aged children with severe exacerbations receiving intensive anticholinergic treatment. The review was updated in 2000 with the addition of three new trials further strengthening the initial conclusions (<a href="./references#CD000060-bbs2-0082" title="PlotnickL , DucharmeF . Combined inhaled anticholinergics and beta2‐agonists for initial treatment of acute asthma in children. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD000060] ">Plotnick 2000</a>). With the identification of seven new studies, the 2012 update aims to examine the conclusions of the earlier version of this review and explore if characteristics of participants or treatment are associated with increased benefit. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD000060-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD000060-sec-0027"></div> <p>To determine whether the addition of inhaled anticholinergics to inhaled SABAs provides clinical improvement and affects the incidence of adverse effects in children with acute asthma exacerbations. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD000060-sec-0028" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD000060-sec-0028"></div> <section id="CD000060-sec-0029"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD000060-sec-0030"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) conducted in an emergency department setting, comparing the combination of an inhaled anticholinergic drug and SABA versus a SABA alone in the treatment of an acute asthma exacerbation. </p> </section> <section id="CD000060-sec-0031"> <h4 class="title">Types of participants</h4> <p>Children aged 18 months to 18 years presenting to an emergency department with an acute exacerbation of asthma. Where studies included children younger than 18 months, we excluded them if the younger children contributed more than 5% of the total study population (post‐hoc decision). </p> </section> <section id="CD000060-sec-0032"> <h4 class="title">Types of interventions</h4> <p>Treatment group: single or repeated doses of nebulized or inhaled short‐acting anticholinergics plus SABAs. </p> <p>Control group: single or repeated doses of nebulized or inhaled placebo plus SABAs.</p> </section> <section id="CD000060-sec-0033"> <h4 class="title">Types of outcome measures</h4> <section id="CD000060-sec-0034"> <h5 class="title">Primary outcomes</h5> <p>Hospital admission.</p> </section> <section id="CD000060-sec-0035"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD000060-list-0001"> <li> <p>Change from baseline in % predicted forced expiratory volume in one second (FEV<sub>1</sub>) (60 and 120 minutes after the last combined anticholinergic and SABA inhalation). </p> </li> <li> <p>Percent change from baseline in FEV<sub>1</sub> (60 and 120 minutes after the last combined inhalation). </p> </li> <li> <p>Change from baseline in respiratory resistance (60 and 120 minutes after the last combined inhalation). </p> </li> <li> <p>Change from baseline in clinical score (60 and 120 minutes after the last combined inhalation). </p> </li> <li> <p>Oxygen saturation (60 and 120 minutes after the last combined inhalation).</p> </li> <li> <p>Need for repeated bronchodilator treatments after the intervention/placebo protocol, prior to disposition. </p> </li> <li> <p>Need for systemic corticosteroids.</p> </li> <li> <p>Adverse effects such as nausea, vomiting and tremor.</p> </li> <li> <p>Relapse rate.</p> </li> </ol> </p> </section> </section> </section> <section id="CD000060-sec-0036"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD000060-sec-0037"> <h4 class="title">Electronic searches</h4> <p>For the previous version of this review, MEDLINE (1966 to April 2000), EMBASE (1980 to April 2000) and CINAHL (1982 to April 2000) were searched using the following MeSH, full text and keyword terms: [asthma, wheez* or respiratory sounds] and [random*, trial*, placebo*, comparative study, controlled study, double‐blind, single‐blind] and [child* or infan* or adolescen* or pediatr* or paediatr*] and [emergenc* or acute*] and [ipratropium* or anticholinerg* or atropin*]. </p> <p>For the 2012 review update, we undertook an 'all years' search of the Cochrane Airways Group Register of Trials with the following terms: anticholinergic* or anti‐cholinergic* or atropine* or ipratropium or tiotropium or oxitropium or Aclidinium) AND ((beta* and agonist) or bronchodilat* or salbutamol or fenoterol or albuterol or terbutaline or metaproterenol) and (child* or paediat* or pediat* or adolesc* or infan* or toddler* or bab* or young* or preschool* or "pre school*" or pre‐school* or newborn* or "new born*" or new‐born* or neo‐nat* or neonat*. </p> </section> <section id="CD000060-sec-0038"> <h4 class="title">Searching other resources</h4> <p>We reviewed bibliographies of all trials and review articles identified through searches to identify potentially relevant citations. We contacted the manufacturer of ipratropium bromide, Boehringer Ingelheim, for the original review and the update, to identify other published or unpublished trials. We contacted trialists working in the field of paediatric asthma to identify potentially relevant trials. </p> </section> </section> <section id="CD000060-sec-0039"> <h3 class="title" id="CD000060-sec-0039">Data collection and analysis</h3> <section id="CD000060-sec-0040"> <h4 class="title">Selection of studies</h4> <p>In the updated search, one review author (BG) examined each new citation (title and abstract) identified through one of the above strategies and classified as clearly included, possibly included or clearly not an RCT. We retrieved and assessed full‐text articles of all citations identified as definite or possible RCTs, irrespective of language of publication. BG and Toby Lasserson (former Managing Editor of the Cochrane Airways Group) assessed the full text independently to determine if the study met the inclusion criteria. We resolved any disagreement by consensus. Emma Welsh (Managing Editor of the Cochrane Airways Group) and Elizabeth Stovold (Trials Search Co‐ordinator of the Cochrane Airways Group) assisted in screening repeat literature searches prior to publication. </p> </section> <section id="CD000060-sec-0041"> <h4 class="title">Data extraction and management</h4> <p>Two review authors independently extracted data from eligible studies and entered data into the <a href="./references#CD000060-sec-0107" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD000060-sec-0042"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>One review author (BG) and one member of the Cochrane Airways Group (TL or EJW) assessed the risk of bias. Agreement was reached independently in each case. We assessed the risk of bias as high, low or unclear in accordance with recommendation in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> for the following domains (<a href="./references#CD000060-bbs2-0067" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>): </p> <p> <ol id="CD000060-list-0002"> <li> <p>random sequence generation (selection bias);</p> </li> <li> <p>allocation concealment (selection bias);</p> </li> <li> <p>blinding (performance bias and detection bias);</p> </li> <li> <p>incomplete outcome data (attrition bias);</p> </li> <li> <p>selective reporting (reporting bias);</p> </li> <li> <p>other bias.</p> </li> </ol> </p> </section> <section id="CD000060-sec-0043"> <h4 class="title">Measures of treatment effect</h4> <p>We analyzed treatment effects for dichotomous outcomes as pooled risk ratios (RR). For continuous outcomes, we used the mean difference (MD) or the standardized mean difference (SMD) to estimate the pooled effect size. For example, the MD was reported for pulmonary function tests using the same unit of measure. We used the SMD, reported in 'standard deviation units', when the change in the same pulmonary function test was reported in different units (change in % predicted FEV<sub>1</sub> and % change in FEV<sub>1</sub>). We presented pooled effect sizes along with the 95% confidence intervals (CI). </p> </section> <section id="CD000060-sec-0044"> <h4 class="title">Dealing with missing data</h4> <p>We attempted to contact the study investigators or study sponsors to verify study methodology and extracted information and to provide additional data if necessary. </p> </section> <section id="CD000060-sec-0045"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used the I<sup>2</sup> statistic for assessing the level of statistical heterogeneity between the results of the studies. We used the following levels of I<sup>2</sup> as a guide: </p> <p> <ul id="CD000060-list-0003"> <li> <p>0% to 40% may not be important;</p> </li> <li> <p>30% to 60% may represent moderate heterogeneity;</p> </li> <li> <p>50% to 90% may represent substantial heterogeneity;</p> </li> <li> <p>75% to 100% considerable heterogeneity.</p> </li> </ul> </p> </section> <section id="CD000060-sec-0046"> <h4 class="title">Assessment of reporting biases</h4> <p>We visually inspected funnel plot symmetry where we had more than 10 trials contributing data to a meta‐analysis in an effort to detect possible biases. </p> </section> <section id="CD000060-sec-0047"> <h4 class="title">Data synthesis</h4> <p>We entered data into Review Manager 5.1 software (<a href="./references#CD000060-bbs2-0072" title="The Nordic Cochrane Centre: The Cochrane Collaboration. Review Manager (RevMan). Version 5.1. Copenhagen: The Nordic Cochrane Centre: The Cochrane Collaboration, 2011. ">RevMan 2011</a>). Treatment effects for dichotomous outcomes were analyzed and reported as pooled RRs using the fixed‐effect model (<a href="./references#CD000060-bbs2-0065" title="GreenlandS , RobinsJM . Estimation of a common effect parameter from sparse follow‐up data. Biometrics1985;41:55‐68. ">Greenland 1985</a>), or, in case of substantial, unexplained heterogeneity, the random‐effects model (<a href="./references#CD000060-bbs2-0062" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). </p> </section> <section id="CD000060-sec-0048"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We postulated a priori that three factors may potentially influence the magnitude or direction, or both, of the therapeutic response, namely: </p> <p> <ol id="CD000060-list-0004"> <li> <p>the intensity of anticholinergic treatment;</p> </li> <li> <p>co‐intervention with glucocorticoids; and</p> </li> <li> <p>the severity of exacerbation (based on documented/reported severity by authors and by tertile of admission rate). </p> </li> </ol> </p> <p>Therefore, RCTs were grouped according to the intensity of anticholinergic protocol (single‐dose regimen, multiple fixed‐dose regimen, multiple flexible‐dose regimen) and stratified on the presence/absence of systemic glucocorticoids. Whenever reported, the baseline % predicted FEV<sub>1</sub> and hospital admission rate in the control groups were recorded as indicators of severity and examined for their potential interaction with therapeutic effect. </p> <p>In order to evaluate the effect of baseline severity on the magnitude of response to the intervention, we stratified trials according to severity documented or reported by authors as per the original review. In addition, we ranked each study in increasing order of the control group admission rate as a proxy for severity. We then split these arbitrarily into tertiles, which we referred to as low, medium or high risk. If the admission rate for a particular study was not available, we did not rank that study. </p> <p>For the 2012 update, we considered adding a subgroup analysis by age of child; however, the overlap in age ranges included in each study precluded this analysis. We considered also doing a subgroup analysis based on cumulative dose of ipratropium delivered. However, this analysis was potentially confounded by the severity of the asthma exacerbation of the children included in the trials as well as differences between the drug delivery methods (nebulizers versus metered‐dose inhalers (MDI) and spacers) and was thus omitted. </p> </section> <section id="CD000060-sec-0049"> <h4 class="title">Sensitivity analysis</h4> <p>We performed sensitivity analyses to examine the effect on results of excluding unpublished trials, those with poor methodological quality and studies that included a small proportion of children under 18 months of age (less than 5% of total study participants). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD000060-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD000060-sec-0050"></div> <section id="CD000060-sec-0051"> <h3 class="title">Description of studies</h3> <section id="CD000060-sec-0052"> <h4 class="title">Results of the search</h4> <p>For the 2012 update, the search retrieved 223 references for screening (18 April 2012). We excluded studies that had already been assessed for inclusion in the first version of the review and obtained 19 citations for full‐text scrutiny. These citations referred to 19 studies (see <a href="./appendices#CD000060-sec-0096">Appendix 1</a> for details of previous search results) and seven new trials met the eligibility criteria for inclusion. </p> </section> <section id="CD000060-sec-0053"> <h4 class="title">Included studies</h4> <section id="CD000060-sec-0054"> <h5 class="title">Trial protocol/dose regimen</h5> <p>Overall, there were 20 included trials and three trials generated additional comparisons. Two studies provided stratified data subgrouped by severity (<a href="./references#CD000060-bbs2-0013" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998</a>; <a href="./references#CD000060-bbs2-0024" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999</a>), and one study evaluated two different dosing strategies against control (<a href="./references#CD000060-bbs2-0017" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995</a>). Overall, there were 24 comparisons. We subgrouped trials according to the intensity of the anticholinergic protocol (see <a href="#CD000060-tbl-0002">Table 1</a>). Six trials on 570 children tested a single dose of ipratropium bromide added to multiple (two to six) doses of SABAs given every 20 to 30 minutes. We termed these the 'single‐dose protocol'. </p> <div class="table" id="CD000060-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study treatments</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age range (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Delivery device</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of ipratropium bromide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of doses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total dose delivered</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>Single dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0001" title="BeckR . Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience [in French] [Utilisation du bromure d'ipratropium par voie inhalée pour le traitement de l'asthme aigu chez l'enfant]. Archives de Pediatrie1995;2 Suppl(2):145‐8. BeckR , RobertsonC , Galdes‐SebaldtM , LevisonH . Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. Journal of Pediatrics1985;107:605‐8. ">Beck 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐17.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MDI and spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0006" title="CookJJ , FergussonDM , DawsonKP . Ipratropium and fenoterol in the treatment of acute asthma. Pharmatherapeutica1985;4(6):383‐6. ">Cook 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐2 mL of 0.025% solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐2 mL of 0.025% solution</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0011" title="PhanichyakamP , KraisarinC , SasisakulpornC . Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pacific Journal of Allergy and Immunology1990;8:45‐8. ">Phanichyakam 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MDI and spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0019" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (single)</a> (single dose) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign=""> <p><b>Multiple fixed‐dose protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 months to 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0009" title="IramainR , Lopez‐HerceJ , CoronelJ , SpittersC , GuggiariJ , BogadoN . inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. Journal of Asthma2011;48:298‐303. ">Iramain 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg children over 20 kg</p> <p>250 mcg children under 20 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3000 mcg or 1500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0014" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998 (moderate)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0015" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐35. ">Qureshi 1998 (severe)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0016" title="ReismanJ , Galdes‐SebaldtM , KazimF , CannyG , LevisonH . Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. Journal of Allergy &amp; Clinical Immunology1988;81:16‐20. ">Reisman 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0017" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995</a> (multiple dose) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0020" title="SharmaA , MadaanA . Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian Journal of Pediatrics2004;71(2):121‐4. ">Sharma 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0021" title="Sienra MongeJJ , Bermejo GuevaraMA , delRio NavarroBE , Rosas VargasMA , Reyes RuizNI . Degree and duration of bronchodilatation with an agonist beta 2 administered alone versus an agonist beta 2 administered with ipratropium bromide in children with acute asthma. Revista Alergia Mexico2000;47(1):26‐9. ">Sienra Monge 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MDI and spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>240 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0022" title="WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children [Abstract]. Chest2004;126(4 Suppl):761S‐b. WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. Annals of Allergy, Asthma, &amp; Immunology2006;96(5):701‐6. ">Watanasomsiri 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0023" title="WatsonWTA , BeckerAB , SimmonsFER . Comparison of ipratropium solution, fenoterol solution and their combination administered by nebulizer and face mask to children with acute asthma. Journal of Allergy &amp; Clinical Immunology1988;82:1012‐8. ">Watson 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0025" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (mild)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0026" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (moderate)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0027" title="ZorcJJ , Pusic , MV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (severe)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Multiple</b> flexible‐<b>dose protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MDI and spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Max 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140 mcg (max)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 months to 13 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05‐0.1 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Max 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15‐0.3 mg/kg (max)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Max: maximum; MDI: metered‐dose inhaler.</p> </div> </div> <p>In 16 intervention arms with 2191 children, doses of ipratropium bromide were administered at multiple fixed time points after the trial began. We termed these trials 'multiple fixed‐dose protocol'. The doses of ipratropium bromide varied from 120 mcg to 500 mcg and the number of doses ranged between two and six over 30 to 90 minutes. </p> <p>Two studies including 84 children added a dose of anticholinergic to every SABA, leaving the number of inhalations determined by the child's need. These were termed 'multiple flexible‐dose protocol'. <a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a> used a fixed dose of ipratropium bromide (20 mcg) given up to seven times in two hours. Treatment was stopped after the child's clinical score dropped below a predetermined threshold. <a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a> used a fixed dose of atropine sulfate (0.05 to 0.1 mg/kg) up to three times at 20‐minute intervals. Treatment was continued until symptoms were controlled or the subject was admitted to hospital. </p> <p>With one exception that used atropine (<a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a>), ipratropium bromide was used as the anticholinergic agent. </p> </section> <section id="CD000060-sec-0055"> <h5 class="title">Participants</h5> <p>Three studies with children younger than 18 months were included (<a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a>; <a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a>; <a href="./references#CD000060-bbs2-0011" title="PhanichyakamP , KraisarinC , SasisakulpornC . Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pacific Journal of Allergy and Immunology1990;8:45‐8. ">Phanichyakam 1990</a>). Only <a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a> reported data for the primary outcome and we tested whether inclusion of this study would unduly affect the analysis (although unlikely, as the mean age of children in the study was 5.7 years). </p> </section> <section id="CD000060-sec-0056"> <h5 class="title">Outcomes</h5> <p>The most frequently reported outcomes were hospital admission rate and spirometric measurements. Nineteen intervention arms (from 16 studies) reported our primary outcome of hospital admission rate. Of note, 84% of the weight in this outcome was contributed by trials focusing on children with documented or reported moderate or severe airway obstruction and 87% of the weight was contributed by trials in the higher and middle tertile of admission rate. Not all trials considered each outcome. The reporting of adverse and side effects was variable. Adverse effects such as hypertension or tachycardia were reported so infrequently that they could not be considered in this review. Whenever reported, we extracted side effects such as nausea, vomiting and tremor, which may interfere with children's compliance. All reported outcomes are listed in the <a href="./references#CD000060-sec-0107" title="">Characteristics of included studies</a> table. </p> </section> <section id="CD000060-sec-0057"> <h5 class="title">Defining severity using admission rate</h5> <p>No single baseline spirometric characteristic was consistently reported across all studies. Hence insufficient lung function data were provided to enable us to determine the asthma severity of children at the start of trials. We ascertained asthma severity in two ways. </p> <p>First, as per the original protocol, we stratified severity using lung function or clinical score at baseline and used both the eligibility/exclusion criteria and the severity reported by authors to confirm our assessment (see <a href="#CD000060-tbl-0003">Table 2</a>). </p> <div class="table" id="CD000060-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Severity based on review author assessment of trial report</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MEAN FEV<sub>1</sub>/PEFR (inclusion criteria)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MEAN score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial report description of severity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Review authors severity classification</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beck 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV 30‐31% (eligibility: FEV<sub>1</sub> &lt; 50% pred) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 years‐upper range not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benito‐Fernandez 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PEF: 45% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 on a 5‐point score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 months to 16 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BI (pers comm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear if measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>severity score of 13 (unknown scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐10 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calvo (1998)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEF = 69‐71% (excluded if PEF &gt; 80% pred.)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐point TAL score: 5.6‐6 (moderate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐14 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chakraborti (2006)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> 69‐71 ± 37% (S+IB) and 57 ± 21% (S alone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐point clinical asthma score 1.83 (S+IB) vs. 2.07 (S alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and moderate  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐15 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ducharme (1998)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children requiring continuous nebulizations of salbutamol were excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild and moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild and moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐7 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iramain (2011)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> 60‐64%/PEF 62‐60% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐point pulmonary score: 12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐18 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pederson (1996)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean not reported (eligibility FEV<sub>1</sub> &lt; 70% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐12 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qureshi (1997)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> and PEF at baseline 37% and 34% (eligibility FEV<sub>1</sub> &lt; 50% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐18 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qureshi (1998) (sev)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup data provided by author:</p> <p>FEV<sub>1</sub> 34% (eligibility FEV<sub>1</sub> &lt; 50% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐15 on 15‐point asthma score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐18 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qureshi (1998) (mod)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup data provided by author:</p> <p>FEV<sub>1</sub> 55% (eligibility: 50% &lt; FEV<sub>1</sub> &lt; 70% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐11 on a 15‐point Clinical score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐18 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reisman (1998)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> 33‐40% (eligibility; FEV<sub>1</sub> &lt; 55% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐15 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schuh (1995)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean FEV<sub>1</sub>‐34% (eligibility; FEV<sub>1</sub> &lt; 50% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>wheezing score 2.2‐2.5 on max of 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐17 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sharma (2004)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEF 35% pred. (excluded PEF &lt; 30% pred. and signs of impending respiratory disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wheezing score 2.5 to 2.6 (max = 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐14 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sienra monge (2000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub>: 1 L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unrated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐15 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Watson (1988)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> not reported (eligibility FEV<sub>1</sub>: 30‐70% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7‐6 on a scale of 0 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐17 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Watanasomsiri (2006)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean % pred. PEFR at baseline 27‐30% in the subset of people cooperating with the forced expiratory technique)(PEFR was not an inclusion criteria) no exclusion or inclusion based on severity </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.42 on a scale of 0 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of moderate asthma: 73% and of severe asthma: 27%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐15 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zorc (1999)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroups data obtained from authors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 strata (mild, moderate and severe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐17 years</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FEV<sub>1</sub>: forced expiratory volume in one second; IB: ipratropium bromide; max: maximum; PEF: peak expiratory flow; PEFR: peak expiratory flow rate; pred.: predicted; S: salbutamol; y.o.: years old. </p> </div> </div> <p>Eight studies were judged as 'severe' (<a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a>; <a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a>; <a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a>; <a href="./references#CD000060-bbs2-0015" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐35. ">Qureshi 1998 (severe)</a>; <a href="./references#CD000060-bbs2-0016" title="ReismanJ , Galdes‐SebaldtM , KazimF , CannyG , LevisonH . Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. Journal of Allergy &amp; Clinical Immunology1988;81:16‐20. ">Reisman 1988</a>; <a href="./references#CD000060-bbs2-0018" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (multiple)</a>; <a href="./references#CD000060-bbs2-0020" title="SharmaA , MadaanA . Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian Journal of Pediatrics2004;71(2):121‐4. ">Sharma 2004</a>; <a href="./references#CD000060-bbs2-0027" title="ZorcJJ , Pusic , MV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (severe)</a>), four studies as 'moderate and severe' (<a href="./references#CD000060-bbs2-0009" title="IramainR , Lopez‐HerceJ , CoronelJ , SpittersC , GuggiariJ , BogadoN . inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. Journal of Asthma2011;48:298‐303. ">Iramain 2011</a>; <a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a>; <a href="./references#CD000060-bbs2-0022" title="WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children [Abstract]. Chest2004;126(4 Suppl):761S‐b. WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. Annals of Allergy, Asthma, &amp; Immunology2006;96(5):701‐6. ">Watanasomsiri 2006</a>; <a href="./references#CD000060-bbs2-0023" title="WatsonWTA , BeckerAB , SimmonsFER . Comparison of ipratropium solution, fenoterol solution and their combination administered by nebulizer and face mask to children with acute asthma. Journal of Allergy &amp; Clinical Immunology1988;82:1012‐8. ">Watson 1988</a>), three studies as moderate (<a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a>; <a href="./references#CD000060-bbs2-0014" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998 (moderate)</a>; <a href="./references#CD000060-bbs2-0026" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (moderate)</a>), two studie as 'mild and moderate ' (<a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a>; <a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a>), and one study as 'mild' (<a href="./references#CD000060-bbs2-0025" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (mild)</a>) asthma. </p> <p><a href="./references#CD000060-bbs2-0021" title="Sienra MongeJJ , Bermejo GuevaraMA , delRio NavarroBE , Rosas VargasMA , Reyes RuizNI . Degree and duration of bronchodilatation with an agonist beta 2 administered alone versus an agonist beta 2 administered with ipratropium bromide in children with acute asthma. Revista Alergia Mexico2000;47(1):26‐9. ">Sienra Monge 2000</a> did not provide enough information to confirm the authors' judgment and was left unrated (it did not provide data for the primary outcome). </p> <p>Next, we used the control group event rate as a proxy for severity. Studies were ranked by the order of the admission rate of the control group, and divided into three groups and labelled as high, medium and low admission rates (see <a href="#CD000060-tbl-0004">Table 3</a>). </p> <div class="table" id="CD000060-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Studies grouped by control group event rate as a proxy for severity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Admission rate</b> </p> <p><b>(control group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline population spirometry characteristics</b> </p> <p><b>(where available)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Admission rate ‐ ranking</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="15" valign=""> <p><b>Multiple fixed‐dose protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEFR (%) mean 44.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0015" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐35. ">Qureshi 1998 (severe)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEFR &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0018" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (multiple)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 50% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEFR &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0009" title="IramainR , Lopez‐HerceJ , CoronelJ , SpittersC , GuggiariJ , BogadoN . inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. Journal of Asthma2011;48:298‐303. ">Iramain 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF or FEV<sub>1</sub> &lt; 60% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0027" title="ZorcJJ , Pusic , MV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (severe)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 70% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0026" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (moderate)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0016" title="ReismanJ , Galdes‐SebaldtM , KazimF , CannyG , LevisonH . Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. Journal of Allergy &amp; Clinical Immunology1988;81:16‐20. ">Reisman 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 55% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0020" title="SharmaA , MadaanA . Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian Journal of Pediatrics2004;71(2):121‐4. ">Sharma 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% predicted PEFR 34.4% (mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0014" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998 (moderate)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEFR &lt; 70% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0022" title="WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children [Abstract]. Chest2004;126(4 Suppl):761S‐b. WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. Annals of Allergy, Asthma, &amp; Immunology2006;96(5):701‐6. ">Watanasomsiri 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% PEFR 29.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0025" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (mild)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0023" title="WatsonWTA , BeckerAB , SimmonsFER . Comparison of ipratropium solution, fenoterol solution and their combination administered by nebulizer and face mask to children with acute asthma. Journal of Allergy &amp; Clinical Immunology1988;82:1012‐8. ">Watson 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Single‐dose protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0019" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (single)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 50% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Respiratory resistance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 80% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>FEV<sub>1</sub>: forced expiratory volume in one second; PEF: peak expiratory flow; PEFR: peak expiratory flow rate. </p> </div> </div> <p>Ranking of severity based on admission rate in the control group corresponded somewhat but not perfectly to ranking based on mean baseline % predicted FEV<sub>1</sub> in the studies that reported it or authors' reports. Ranking on admission rate permitted the inclusion of studies that did not use spirometry or did not report mean baseline % predicted FEV<sub>1</sub>. The ranking admission rate varied from 0 to 0.53. </p> <p>Studies from the multiple dose‐fixed and single‐dose protocols provided hospital admission data and were, therefore, ranked in this manner. </p> <p>We define six intervention arms from 'multiple dose‐fixed protocol' trials as a high admission rate (<a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a>; <a href="./references#CD000060-bbs2-0009" title="IramainR , Lopez‐HerceJ , CoronelJ , SpittersC , GuggiariJ , BogadoN . inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. Journal of Asthma2011;48:298‐303. ">Iramain 2011</a>; <a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a>; <a href="./references#CD000060-bbs2-0015" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐35. ">Qureshi 1998 (severe)</a>; <a href="./references#CD000060-bbs2-0018" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (multiple)</a>; <a href="./references#CD000060-bbs2-0019" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (single)</a>), six as medium admission rate (<a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a>; <a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a>; <a href="./references#CD000060-bbs2-0016" title="ReismanJ , Galdes‐SebaldtM , KazimF , CannyG , LevisonH . Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. Journal of Allergy &amp; Clinical Immunology1988;81:16‐20. ">Reisman 1988</a>; <a href="./references#CD000060-bbs2-0020" title="SharmaA , MadaanA . Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian Journal of Pediatrics2004;71(2):121‐4. ">Sharma 2004</a>; <a href="./references#CD000060-bbs2-0026" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (moderate)</a>; <a href="./references#CD000060-bbs2-0027" title="ZorcJJ , Pusic , MV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (severe)</a>), and six as low admission rate (<a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a>; <a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a>; <a href="./references#CD000060-bbs2-0014" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998 (moderate)</a>; <a href="./references#CD000060-bbs2-0022" title="WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children [Abstract]. Chest2004;126(4 Suppl):761S‐b. WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. Annals of Allergy, Asthma, &amp; Immunology2006;96(5):701‐6. ">Watanasomsiri 2006</a>; <a href="./references#CD000060-bbs2-0023" title="WatsonWTA , BeckerAB , SimmonsFER . Comparison of ipratropium solution, fenoterol solution and their combination administered by nebulizer and face mask to children with acute asthma. Journal of Allergy &amp; Clinical Immunology1988;82:1012‐8. ">Watson 1988</a>; <a href="./references#CD000060-bbs2-0025" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (mild)</a>). We were unable to rank six studies because admission rates were not provided (<a href="./references#CD000060-bbs2-0001" title="BeckR . Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience [in French] [Utilisation du bromure d'ipratropium par voie inhalée pour le traitement de l'asthme aigu chez l'enfant]. Archives de Pediatrie1995;2 Suppl(2):145‐8. BeckR , RobertsonC , Galdes‐SebaldtM , LevisonH . Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. Journal of Pediatrics1985;107:605‐8. ">Beck 1985</a>; <a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a>; <a href="./references#CD000060-bbs2-0006" title="CookJJ , FergussonDM , DawsonKP . Ipratropium and fenoterol in the treatment of acute asthma. Pharmatherapeutica1985;4(6):383‐6. ">Cook 1985</a>; <a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a>; <a href="./references#CD000060-bbs2-0011" title="PhanichyakamP , KraisarinC , SasisakulpornC . Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pacific Journal of Allergy and Immunology1990;8:45‐8. ">Phanichyakam 1990</a>; <a href="./references#CD000060-bbs2-0021" title="Sienra MongeJJ , Bermejo GuevaraMA , delRio NavarroBE , Rosas VargasMA , Reyes RuizNI . Degree and duration of bronchodilatation with an agonist beta 2 administered alone versus an agonist beta 2 administered with ipratropium bromide in children with acute asthma. Revista Alergia Mexico2000;47(1):26‐9. ">Sienra Monge 2000</a>). </p> </section> </section> <section id="CD000060-sec-0058"> <h4 class="title">Excluded studies</h4> <p>We excluded 30 studies; common reasons for exclusion of studies were: studies on people with chronic or stable asthma (N = 13), hospitalised people (N = 6), inappropriate protocols (e.g. different SABAs in each arm or SABAs at different doses) (N = 4), adults (N = 3), infants (N = 2), non‐randomized control trials (N = 2) and conference abstracts (N = 2). Full details are given in the <a href="./references#CD000060-sec-0108" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD000060-sec-0059"> <h3 class="title">Risk of bias in included studies</h3> <p>The judgment for each risk of bias domain for each study is included in the <a href="./references#CD000060-sec-0107" title="">Characteristics of included studies</a> table and an overview is given in <a href="#CD000060-fig-0001">Figure 1</a>. Methodology of nine of the 19 trials was confirmed by the authors (<a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a>; <a href="./references#CD000060-bbs2-0006" title="CookJJ , FergussonDM , DawsonKP . Ipratropium and fenoterol in the treatment of acute asthma. Pharmatherapeutica1985;4(6):383‐6. ">Cook 1985</a>; <a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a>; <a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a>; <a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a>; <a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a>; <a href="./references#CD000060-bbs2-0015" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐35. ">Qureshi 1998 (severe)</a>; <a href="./references#CD000060-bbs2-0017" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995</a>; <a href="./references#CD000060-bbs2-0026" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (moderate)</a>). </p> <div class="figure" id="CD000060-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgments about each methodological quality item for each included study." data-id="CD000060-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgments about each methodological quality item for each included study. </p> </div> </div> </div> <section id="CD000060-sec-0060"> <h4 class="title">Allocation</h4> <p>We considered 10 studies to be at low risk of selection bias: randomisation was performed using computer‐generated random numbers in six studies (<a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a>; <a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a>; <a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a>; <a href="./references#CD000060-bbs2-0009" title="IramainR , Lopez‐HerceJ , CoronelJ , SpittersC , GuggiariJ , BogadoN . inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. Journal of Asthma2011;48:298‐303. ">Iramain 2011</a>; <a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a>; <a href="./references#CD000060-bbs2-0025" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (mild)</a>), tables of random numbers in three trials (<a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a>; <a href="./references#CD000060-bbs2-0013" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998</a>; <a href="./references#CD000060-bbs2-0018" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (multiple)</a>; <a href="./references#CD000060-bbs2-0019" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (single)</a>), and one trial used block randomisation (<a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a>). Nine studies did not describe the method of randomisation and were classified as unclear risk of bias, one study used consecutive assignment and was judged to be at high risk of bias (<a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a>). </p> <p>We considered 14 trials to be at low risk of bias for allocation concealment; 12 studies used number‐coded solutions supplied by the pharmacy (<a href="./references#CD000060-bbs2-0001" title="BeckR . Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience [in French] [Utilisation du bromure d'ipratropium par voie inhalée pour le traitement de l'asthme aigu chez l'enfant]. Archives de Pediatrie1995;2 Suppl(2):145‐8. BeckR , RobertsonC , Galdes‐SebaldtM , LevisonH . Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. Journal of Pediatrics1985;107:605‐8. ">Beck 1985</a>; <a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a>; <a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a>; <a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a>; <a href="./references#CD000060-bbs2-0009" title="IramainR , Lopez‐HerceJ , CoronelJ , SpittersC , GuggiariJ , BogadoN . inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. Journal of Asthma2011;48:298‐303. ">Iramain 2011</a>; <a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a>; <a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a>; <a href="./references#CD000060-bbs2-0014" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998 (moderate)</a>; <a href="./references#CD000060-bbs2-0016" title="ReismanJ , Galdes‐SebaldtM , KazimF , CannyG , LevisonH . Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. Journal of Allergy &amp; Clinical Immunology1988;81:16‐20. ">Reisman 1988</a>; <a href="./references#CD000060-bbs2-0019" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (single)</a>; <a href="./references#CD000060-bbs2-0022" title="WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children [Abstract]. Chest2004;126(4 Suppl):761S‐b. WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. Annals of Allergy, Asthma, &amp; Immunology2006;96(5):701‐6. ">Watanasomsiri 2006</a>; <a href="./references#CD000060-bbs2-0025" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (mild)</a>), one study used opaque consecutive numbered envelopes containing assignment (<a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a>), and one study "used a person not involved in the study" (<a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a>). Allocation concealment was at unclear risk of bias in the remaining six studies. </p> </section> <section id="CD000060-sec-0061"> <h4 class="title">Blinding</h4> <p>Sixteen studies claimed double‐blinding while two were described as triple‐blind (<a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a>; <a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a>), and two were unblinded (<a href="./references#CD000060-bbs2-0011" title="PhanichyakamP , KraisarinC , SasisakulpornC . Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pacific Journal of Allergy and Immunology1990;8:45‐8. ">Phanichyakam 1990</a>; <a href="./references#CD000060-bbs2-0020" title="SharmaA , MadaanA . Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian Journal of Pediatrics2004;71(2):121‐4. ">Sharma 2004</a>). Twelve studies used an identical placebo in the control group, one study described a similarly looking intervention and placebo solutions (<a href="./references#CD000060-bbs2-0006" title="CookJJ , FergussonDM , DawsonKP . Ipratropium and fenoterol in the treatment of acute asthma. Pharmatherapeutica1985;4(6):383‐6. ">Cook 1985</a>), and three studies did not provide details of the blinding method (<a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a>; <a href="./references#CD000060-bbs2-0021" title="Sienra MongeJJ , Bermejo GuevaraMA , delRio NavarroBE , Rosas VargasMA , Reyes RuizNI . Degree and duration of bronchodilatation with an agonist beta 2 administered alone versus an agonist beta 2 administered with ipratropium bromide in children with acute asthma. Revista Alergia Mexico2000;47(1):26‐9. ">Sienra Monge 2000</a>; <a href="./references#CD000060-bbs2-0023" title="WatsonWTA , BeckerAB , SimmonsFER . Comparison of ipratropium solution, fenoterol solution and their combination administered by nebulizer and face mask to children with acute asthma. Journal of Allergy &amp; Clinical Immunology1988;82:1012‐8. ">Watson 1988</a>). It was assumed that the person making the decision to admit to hospital was also blinded to the medication received but only one study described them as blinded (<a href="./references#CD000060-bbs2-0017" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995</a>). </p> </section> <section id="CD000060-sec-0062"> <h4 class="title">Incomplete outcome data</h4> <p>Thirteen studies reported the presence/absence of participant withdrawal or dropout and the reasons for the attrition if applicable (<a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a>; <a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a>; <a href="./references#CD000060-bbs2-0006" title="CookJJ , FergussonDM , DawsonKP . Ipratropium and fenoterol in the treatment of acute asthma. Pharmatherapeutica1985;4(6):383‐6. ">Cook 1985</a>; <a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a>; <a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a>; <a href="./references#CD000060-bbs2-0009" title="IramainR , Lopez‐HerceJ , CoronelJ , SpittersC , GuggiariJ , BogadoN . inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. Journal of Asthma2011;48:298‐303. ">Iramain 2011</a>; <a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a>; <a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a>; <a href="./references#CD000060-bbs2-0014" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998 (moderate)</a>; <a href="./references#CD000060-bbs2-0017" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995</a>; <a href="./references#CD000060-bbs2-0022" title="WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children [Abstract]. Chest2004;126(4 Suppl):761S‐b. WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. Annals of Allergy, Asthma, &amp; Immunology2006;96(5):701‐6. ">Watanasomsiri 2006</a>; <a href="./references#CD000060-bbs2-0023" title="WatsonWTA , BeckerAB , SimmonsFER . Comparison of ipratropium solution, fenoterol solution and their combination administered by nebulizer and face mask to children with acute asthma. Journal of Allergy &amp; Clinical Immunology1988;82:1012‐8. ">Watson 1988</a>; <a href="./references#CD000060-bbs2-0027" title="ZorcJJ , Pusic , MV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (severe)</a>). One study referred to 40 children in the abstract but presented data for only 30 children with no clear explanation (<a href="./references#CD000060-bbs2-0021" title="Sienra MongeJJ , Bermejo GuevaraMA , delRio NavarroBE , Rosas VargasMA , Reyes RuizNI . Degree and duration of bronchodilatation with an agonist beta 2 administered alone versus an agonist beta 2 administered with ipratropium bromide in children with acute asthma. Revista Alergia Mexico2000;47(1):26‐9. ">Sienra Monge 2000</a>). </p> </section> <section id="CD000060-sec-0063"> <h4 class="title">Selective reporting</h4> <p>One study recorded data for hospital admission but did not publish the data and commented that the "hospital admission data was not significant" (<a href="./references#CD000060-bbs2-0001" title="BeckR . Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience [in French] [Utilisation du bromure d'ipratropium par voie inhalée pour le traitement de l'asthme aigu chez l'enfant]. Archives de Pediatrie1995;2 Suppl(2):145‐8. BeckR , RobertsonC , Galdes‐SebaldtM , LevisonH . Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. Journal of Pediatrics1985;107:605‐8. ">Beck 1985</a>). </p> </section> </section> <section id="CD000060-sec-0064"> <h3 class="title" id="CD000060-sec-0064">Effects of interventions</h3> <p>See: <a href="./full#CD000060-tbl-0001"><b>Summary of findings for the main comparison</b> Anticholinergic and short‐acting beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols) for initial treatment of acute asthma in children</a> </p> <p>First we present the primary outcome with all protocols, then we present the prespecified subgroup analyses (trial protocol, severity, co‐intervention of corticosteroid) followed by the secondary outcomes. We did not subgroup the secondary outcomes. </p> <section id="CD000060-sec-0065"> <h4 class="title">Primary outcome: admission to hospital</h4> <p>When anticholinergics were delivered in addition to SABAs, there was a significant decrease in the risk of hospital admission versus SABAs and placebo (RR 0.73; 95% CI 0.63 to 0.85; <a href="#CD000060-fig-0002">Figure 2</a>). The primary analysis was inclusive of all study protocols (single dose, multiple‐fixed and multiple‐flexible); however, only studies using single and multiple‐fixed dose protocols reported data for this outcome. Fifteen studies (nineteen comparisons) reported data for this outcome, but the absence of admission in three studies mean that the pooled RR was based on data from 16 comparisons (2326 children). The result was statistically significant (P value &lt; 0.0001) and there was no evidence of statistical heterogeneity between the study results (I<sup>2</sup> = 0%). In the children receiving SABAs only, 23 people out of 100 were admitted to hospital compared with 17 (95% CI 15 to 20) out of 100 for children receiving SABAs plus anticholinergics (<a href="#CD000060-fig-0003">Figure 3</a>). This represents an overall number needed to treat for an additional beneficial effect (NNTB) of 16 (95% CI 12 to 29). </p> <div class="figure" id="CD000060-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 1 Anticholinergic and short‐acting beta2‐agonists versus short‐acting beta2‐agonists alone (all protocols), outcome: 1.1 Primary outcome: hospital admissions." data-id="CD000060-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anticholinergic and short‐acting beta<sub>2</sub>‐agonists versus short‐acting beta<sub>2</sub>‐agonists alone (all protocols), outcome: 1.1 Primary outcome: hospital admissions. </p> </div> </div> </div> <div class="figure" id="CD000060-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="In the children on short‐acting beta2‐agonists only, 23 people out of 100 were admitted to hospital, compared with 17 (95% CI 15 to 20) out of 100 for children on short‐acting beta2‐agonists plus anticholinergics." data-id="CD000060-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>In the children on short‐acting beta<sub>2</sub>‐agonists only, 23 people out of 100 were admitted to hospital, compared with 17 (95% CI 15 to 20) out of 100 for children on short‐acting beta<sub>2</sub>‐agonists plus anticholinergics. </p> </div> </div> </div> <p>A funnel plot of the results for this outcome did not appear to indicate obvious signs of publication bias (<a href="#CD000060-fig-0004">Figure 4</a>). </p> <div class="figure" id="CD000060-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Funnel plot of analysis 1.1." data-id="CD000060-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of analysis 1.1.</p> </div> </div> </div> </section> <section id="CD000060-sec-0066"> <h4 class="title">Primary outcome: admission to hospital: subgroup analysis by study protocol</h4> <p>Subgrouping the studies by study protocol for the same outcome showed no statistically significant difference between subgroups (test for subgroup differences: Chi<sup>2</sup> = 0.55, degrees of freedom (df) = 1, P value = 0.46, I<sup>2</sup> = 0%), although the power was low due to marked group imbalances in weight (<a href="./references#CD000060-fig-0006" title="">Analysis 1.2</a>). Fifteen intervention arms including 1998 children were subgrouped into the multiple fixed‐dose protocol group. Of interest, anticholinergics delivered as a multiple fixed‐dose regimen in 11 studies on 1998 children led to a decrease in the risk of hospital admission by 28% compared with SABA alone (RR 0.72; 95% CI 0.61 to 0.84). This result was statistically significant (P value &lt; 0.0001) with no evidence of heterogeneity (I<sup>2</sup> = 0%). However, pooling data from only three studies (including 419 children) that used a single‐dose regimen showed no significant reduction in risk (RR 0.84; 95% CI 0.56 to 1.26). Studies grouped into the multiple flexible‐dose protocol did not provide data for this outcome. Due to subgroup imbalance in number and severity, we cannot firmly conclude on whether the intensity of therapy makes a difference in the magnitude of effect of treatment. </p> </section> <section id="CD000060-sec-0067"> <h4 class="title">Primary outcome: admission to hospital: subgroup analysis by author's judgment of asthma severity and control group admission rate (multiple dose ‐ fixed protocol) </h4> <p>Efforts had been made in previous versions of this review to stratify studies by asthma severity based on baseline lung function or clinical score and validated by both the eligibility and exclusion criteria and the authors' assessment of severity (<a href="#CD000060-tbl-0003">Table 2</a>). The studies were classified as severe, moderate and severe, moderate, mild and moderate, and mild. There was no significant difference between the RRs in these severity subgroups (test for subgroup differences: Chi<sup>2</sup> = 2.58, df = 4, P value = 0.63, I<sup>2</sup> = 0%; <a href="./references#CD000060-fig-0007" title="">Analysis 1.3</a>). Admittedly, the number of subgroups may have decreased the power to detect statistically significant subgroup differences. </p> <p>In the eight studies including 1188 children, judged as experiencing a severe asthma exacerbation, a 27% decrease in the risk of admission (RR 0.73; 95% CI 0.61 to 0.87) was observed with anticholinergic treatment. </p> <p>In the four studies including 371 children, rated as having a moderate or severe asthma exacerbation, a 40% reduction in risk of hospitalisation (RR 0.60; 95% CI 0.41 to 0.89) was documented in favor of anticholinergic treatment. In the three studies with 463 children experiencing a moderate asthma exacerbation, no significant reduction in risk of hospitalisation (RR 0.77; 95% 0.49 to 1.22) was observed although the effect size was of similar magnitude to that in the preceding groups. </p> <p>Two studies including 358 children experiencing mild and moderate asthma exacerbations showed a non‐significant reduction in hospital admission (RR 0.87; 95% CI 0.52 to 1.47). </p> <p>In 117 children judged as experiencing a mild asthma exacerbation, there was no apparent beneficial effect on hospital admission with a wide confidence interval (RR 1.43; 95% CI 0.42 to 4.79). </p> <p>In this review update, we subgrouped hospital admissions using our proxy measure for severity derived from the control group event rate for hospitalisation (see <a href="#CD000060-tbl-0004">Table 3</a>). The studies were grouped into tertiles corresponding to high, medium and low risk of admission (high risk, admission rate ≥ 43%; medium risk, admission rate 10% to 42%; and low risk &lt; 10%). There was no significant difference between the RRs in the severity subgroups (test for subgroup differences: Chi<sup>2</sup> = 1.68, df = 2, P value = 0.43, I<sup>2</sup> = 0%). </p> <p>Six studies on 669 children were grouped in the upper tertile with the highest control group admission rates: there was a 32% decrease in the risk of admission with the use of anticholinergics (RR 0.68; 95% CI 0.56 to 0.82; <a href="./references#CD000060-fig-0008" title="">Analysis 1.4</a>). In the six studies on 780 children in the medium‐risk group, the use of anticholinergics reduced the risk of admission by 25% (RR 0.75; 95% CI 0.57 to 0.99). In the subgroup with the lowest control group event rates that included six studies on 968 children, the use of anticholinergics did not significantly reduce the risk of hospital admission (RR 0.91; 95% CI 0.59 to 1.42). Comparing the control group weighted risk against the treatment group's risk, the NNTB in the high‐risk group was 7 (95% CI 5 to 12) versus 17 (95% CI 10 to 415) in the medium‐risk group and 139 (not statistically significant) in the low‐risk group (see <a href="#CD000060-tbl-0005">Table 4</a>). </p> <div class="table" id="CD000060-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Number needed to treat for hospital admissions grouped by severity tertile</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk tertile</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Weighted control group risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Corresponding treatment group risk (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNTB (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.59 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7% (4 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>139 (not significant)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.57 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18% (14 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (10 to 415)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.56 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33% (27 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (5 to 12)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Comparing the control group weighted risk against the treatment group's risk it can be seen that the NNTB in the high risk group was 7 versus 13 in the medium‐risk group and 131 in the low‐risk group. </p> <p>CI: confidence interval; NNTB: number need to treat for an additional beneficial effect.</p> </div> </div> <p>Irrespective of the methods to classify severity, the findings would suggest that, within this group of trials of children with predominantly moderate and severe asthma, those with the most severe airway obstruction and a baseline risk of admission of more than 40% showed the largest numerical benefit from the addition of anticholinergics, with an intermediate effect in those with moderate airway obstruction or a baseline risk of admission between 10% and 40% and no significant effect in the few trials pertaining only to children with mild asthma. </p> </section> <section id="CD000060-sec-0068"> <h4 class="title">Primary outcome: admission to hospital: subgroup analysis by co‐intervention with corticosteroids </h4> <p>Studies were grouped by co‐intervention with corticosteroids (<a href="./references#CD000060-fig-0009" title="">Analysis 1.5</a>). There was no significant difference between the subgroups (test for subgroup differences: Chi<sup>2</sup> = 0.66, df = 3, P value = 0.88, I<sup>2</sup> = 0%). In the eight studies that administered corticosteroids to all children, the addition of an anticholinergic showed a reduction in the risk of hospital admission (RR 0.71; 95% CI 0.59 to 0.86). In the six studies that did not give corticosteroids to all children, the addition of an anticholinergic showed a significant reduction in risk (RR 0.67; 95% CI 0.47 to 0.94). In the three studies that administered corticosteroids at the physician's discretion, the point estimate was similar, but the confidence interval crossed unity (RR 0.77; 95% CI 0.54 to 1.10). This subgroup analysis would suggest that the effect of an anticholinergic was present, independently from the administration of systemic corticosteroids. </p> <section id="CD000060-sec-0069"> <h5 class="title">Secondary outcomes: lung function</h5> <p>Five studies on 402 children reported data for change in % predicted FEV<sub>1</sub> across two study protocols (single‐ and multiple‐dose protocols) (<a href="./references#CD000060-fig-0010" title="">Analysis 1.6</a>). Children treated with an anticholinergic showed a significant improvement from baseline in % predicted FEV<sub>1</sub> at 60 minutes compared to those treated with SABA alone (MD 10.08; 95% CI 6.24 to 13.92). Two studies on 117 children reported data for the same outcome at 120 minutes (<a href="./references#CD000060-fig-0011" title="">Analysis 1.7</a>), which also showed a statistically significant improvement in % predicted FEV<sub>1</sub> in the treatment group versus the control group (MD 6.87; 95% CI 1.17 to 12.56). Fewer studies provided data for change in absolute FEV<sub>1</sub> or in peak expiratory flow rate (PEFR) at 60 minutes (<a href="./references#CD000060-fig-0012" title="">Analysis 1.8</a>) or 120 minutes (<a href="./references#CD000060-fig-0013" title="">Analysis 1.9</a>); although in both cases appeared to favor the use of salbutamol plus an anticholinergic over salbutamol alone, it was only statistically significant at 60 minutes (SMD 0.57; 95% CI 0.25 to 0.88). </p> </section> <section id="CD000060-sec-0070"> <h5 class="title">Secondary outcome: respiratory resistance</h5> <p>In a post hoc analysis of one trial examining 294 children with mild to moderate exacerbations, stratified on concurrent use of systemic corticosteroids, no statistically significant group difference in respiratory resistance observed at 60 minutes (<a href="./references#CD000060-fig-0014" title="">Analysis 1.10</a>) and at 120 minutes (<a href="./references#CD000060-fig-0015" title="">Analysis 1.11</a>) suggesting no significant influence of concurrent corticosteroids on the magnitude of effect associated with a single dose of ipratropium bromide (<a href="http://www.archie.cochrane.org/sections/documents/view?version=4B26BA4782E26AA20079F0EC584B316B%26format=REVMAN#STD-Ducharme-1998" target="_blank">Ducharme 1998</a>). </p> </section> <section id="CD000060-sec-0071"> <h5 class="title">Secondary outcome: change in clinical score</h5> <p>No studies provided data on clinical score at 60 minutes; however, three studies on 934 children provided data for clinical score at 120 minutes. Of these three studies, only two included means with standard deviations. Combining these two results showed that subjects treated with an anticholinergic had a greater improvement in clinical score at 120 minutes (SMD ‐0.23; 95% CI ‐0.42 to ‐0.04; <a href="./references#CD000060-fig-0016" title="">Analysis 1.12</a>). </p> </section> <section id="CD000060-sec-0072"> <h5 class="title">Secondary outcome: oxygen (O<sub>2</sub>) saturation at 60 minutes post therapy </h5> <p>In two trials reporting data for oxygen saturation there was a significant group difference at 60 minutes (RR 0.73; 95% CI 0.55 to 0.97; 415 children; <a href="./references#CD000060-fig-0018" title="">Analysis 1.14</a>), but not at 120 minutes (RR 1.10; 95% CI 0.76 to 1.59; 185 children; <a href="./references#CD000060-fig-0019" title="">Analysis 1.15</a>). </p> </section> <section id="CD000060-sec-0073"> <h5 class="title">Secondary outcome: need for repeat bronchodilator treatment required after standard protocol prior to disposition </h5> <p>Nine studies on 1074 children reported data for the number of children who required repeat treatments of bronchodilator after the study protocol finished and before discharge. Subjects treated with the anticholinergic protocol were 13% less likely to require a repeat bronchodilator treatment before discharge (RR 0.87; 95% CI 0.79 to 0.97; <a href="./references#CD000060-fig-0017" title="">Analysis 1.13</a>). </p> </section> <section id="CD000060-sec-0074"> <h5 class="title">Secondary outcome: adverse events (tremor, vomiting and nausea)</h5> <p>Adverse events reported included tremor, vomiting and nausea. Analysis of nine studies on 524 children showed that children treated with the addition of an anticholinergic were significantly less likely to experience tremor than those treated with inhaled SABAs alone (RR 0.69; 95% CI 0.51 to 0.93; <a href="./references#CD000060-fig-0021" title="">Analysis 1.17</a>). Similarly, analysis of seven studies including 757 children showed that children treated with an anticholinergic were significantly less likely to suffer from nausea (RR 0.60; 95% CI 0.38 to 0.95; <a href="./references#CD000060-fig-0023" title="">Analysis 1.19</a>). Analysis of eight studies on 1230 children observed no statistically significant group difference on vomiting (RR 0.88; 95% CI 0.49 to 1.56; <a href="./references#CD000060-fig-0022" title="">Analysis 1.18</a>). </p> </section> <section id="CD000060-sec-0075"> <h5 class="title">Secondary outcome: relapse</h5> <p>Ten studies on 1389 children reported the relapse rate of children initially discharged from the emergency department during the follow‐up period. No statistically significant difference between groups was observed (RR 1.07; 95% CI 0.68 to 1.68; <a href="./references#CD000060-fig-0024" title="">Analysis 1.20</a>). </p> </section> <section id="CD000060-sec-0076"> <h5 class="title">Sensitivity analysis</h5> <p>Three sensitivity analyses were performed to examine the impact of unpublished data, the inclusion of studies with very young children and inclusion of trials with lower reported methodological quality. </p> <p>Excluding the two unpublished studies (<a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a>; <a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a>) from the primary outcome (all treatment protocols) did not alter the direction or significance level of the risk of admission (RR 0.72; 95% CI 0.61 to 0.84). </p> <p>Of the three included studies that included children under 18 months of age (<a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a>; <a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a>; <a href="./references#CD000060-bbs2-0011" title="PhanichyakamP , KraisarinC , SasisakulpornC . Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pacific Journal of Allergy and Immunology1990;8:45‐8. ">Phanichyakam 1990</a>), only <a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a> contributed data to the primary outcome. Removing this study from the primary outcome (all treatment protocols) made very little difference to the overall result and no impact on the statistical significance (RR 0.74; 95% CI 0.63 to 0.86). </p> <p>Excluding the five studies (<a href="./references#CD000060-bbs2-0001" title="BeckR . Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience [in French] [Utilisation du bromure d'ipratropium par voie inhalée pour le traitement de l'asthme aigu chez l'enfant]. Archives de Pediatrie1995;2 Suppl(2):145‐8. BeckR , RobertsonC , Galdes‐SebaldtM , LevisonH . Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. Journal of Pediatrics1985;107:605‐8. ">Beck 1985</a>; <a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a>; <a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a>; <a href="./references#CD000060-bbs2-0011" title="PhanichyakamP , KraisarinC , SasisakulpornC . Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pacific Journal of Allergy and Immunology1990;8:45‐8. ">Phanichyakam 1990</a>; <a href="./references#CD000060-bbs2-0020" title="SharmaA , MadaanA . Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian Journal of Pediatrics2004;71(2):121‐4. ">Sharma 2004</a>) with lower reported methodological quality and thus at higher risk of bias also did not alter the direction or significance level of the result (RR 0.74; 95% CI 0.64 to 0.86). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD000060-sec-0077" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD000060-sec-0077"></div> <section id="CD000060-sec-0078"> <h3 class="title" id="CD000060-sec-0078">Summary of main results</h3> <section id="CD000060-sec-0079"> <h4 class="title">Primary outcome: hospital admissions</h4> <p>In children with predominantly moderate and severe asthma exacerbation, the combination of an anticholinergic and SABA significantly reduced the risk of hospital admission, the primary outcome of this review. This result was derived from 15 studies (19 comparisons) and 2497 children. Does this result alone justify the use of an anticholinergic in the treatment of all children with acute asthma? To investigate this further we performed several subgroup analyses and considered the validity of these results and their significance for practice. </p> </section> <section id="CD000060-sec-0080"> <h4 class="title">Different treatment protocols used in the trials</h4> <p>An anticholinergic was administered as a single dose, multiple doses according to a fixed protocol, or a flexible dosing regimen where the an anticholinergic was systematically added to every SABA treatment until sufficient clinical improvement for discharge. This fundamental difference in treatment protocols prompted the first subgroup analysis by study protocol. The majority of data came from trials using multiple doses of ipratropium added to inhaled SABA with a fixed protocol: these trials used doses between 250 mcg and 500 mcg usually via a nebulizer device, with all but one using two or three doses over 30 to 90 minutes. There was a 28% statistically significant reduction in the risk of hospital admission in favor of anticholinergics. The three trials using a single‐dose protocol showed a smaller effect size that was not statistically significant and there were no admission data in the two trials using a flexible protocol. In absence of significant group difference in this analysis and the absence of head‐to‐head comparison between treatment protocols, there is insufficient information to judge how these different treatment protocols compare with each other. Until further data are available, it seems reasonable to recommend repeated doses of ipratropium bromide in a fixed protocol for one to two hours. </p> </section> <section id="CD000060-sec-0081"> <h4 class="title">Asthma exacerbation severity</h4> <p>Examining participant characteristics and study author's classification of severity, it was evident that the overwhelming majority of trials were conducted in children with moderate or severe asthma, or both (not unexpected for studies performed in emergency departments). When the trials were broken down into severity subgroups based on the rate of admission to hospital in the control group (given inhaled SABAs alone) or based on lung function and clinical score, there was no significant difference between the severity subgroups. </p> <p>The strongest evidence for a 32% and 25% statistically significant reduction in the risk of admission to hospital with an additional inhaled anticholinergic was seen from the trials classified with a high and medium admission rate, respectively, and while no evidence of effect was noted in the subgroup with the lowest admission rates, the small sample in this latter subgroup reduced the precision of this observation. Seven children (95% CI 5 to 12) needed to be treated in the high admission rate subgroup to prevent one hospital admission versus 17 (95% CI 10 to 415) in the medium admission rate subgroup and 139 (not statistically significant) in the low admission rate subgroup (see <a href="#CD000060-tbl-0005">Table 4</a>). Similarly, although there was no overall statistically significant subgroup difference when severity was based on lung function and clinical score, there was evidence of effect in all severity subgroups but those classified in the mild and mild‐moderate severity subgroups. We underline that, irrespective of the severity classification used, as the CIs for these subgroups were overlapping, there was no significant difference in RR or risk difference between the severity subgroups in this group of predominantly moderate and severe children. Until further data are available, it seems prudent to recommend the addition of anticholinergics in children with moderate or severe exacerbations. </p> </section> <section id="CD000060-sec-0082"> <h4 class="title">Use of systemic corticosteroids</h4> <p>As the use of corticosteroids for the treatment of acute asthma is widely established in practice, we explored the possibility of effect modification by co‐intervention with oral corticosteroids (<a href="./references#CD000060-bbs2-0059" title="British Thoracic Society and Scottish intercollegiate Guidelines Network. British guideline on the management of asthma: a national clinical guideline, 2011. www.brit‐thoracic.org.uk/guidelines (accessed 8 August 2013). ">BTS 2011</a>; <a href="./references#CD000060-bbs2-0064" title="Global INitiative forAsthma . Global strategy for asthma management and prevention, 2011. www.ginasthma.org (accessed 8 August 2013). ">GINA 2011</a>; <a href="./references#CD000060-bbs2-0070" title="LougheedMD , LemiereC , DucharmeFM , LicskaiC , DellSD , RoweBH , et al. Canadian Thoracic Society 2012 guideline update: diagnosis and management of asthma in preschoolers, children and adults. Canadian Respiratory Journal2012; Vol. 19, issue 2:127‐64. [1916‐7245: (Electronic)] ">Lougheed 2012</a>; <a href="./references#CD000060-bbs2-0074" title="RoweBH , SpoonerC , DucharmeF , BretziaffJ , BotaG . Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database of Systematic Reviews2001, Issue 1. [DOI: 10.1002/14651858.CD002178] ">Rowe 2001</a>)<i>.</i> There was some variation in the use of corticosteroids between studies; corticosteroids were either not used, were systematically used or their use was left to the discretion of the attending physician. We found no statistically significant group difference between the subgroups that did or did not administer systemic corticosteroids and no apparent difference in the size of the effect of an anticholinergic. This suggests that the effect of anticholinergics is not influenced by co‐intervention with systemic corticosteroids, at least not within two to three hours of corticosteroid administration (mean time to decision to admit in studies contributing data to the primary outcome two to three hours). This may be due to the delayed onset of action of systemic corticosteroids three to four hours after administration (<a href="./references#CD000060-bbs2-0074" title="RoweBH , SpoonerC , DucharmeF , BretziaffJ , BotaG . Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database of Systematic Reviews2001, Issue 1. [DOI: 10.1002/14651858.CD002178] ">Rowe 2001</a>). </p> </section> <section id="CD000060-sec-0083"> <h4 class="title">Other subgroups</h4> <p>Further subgroup analyses were considered for the 2012 update, but not performed. Analysis by age of child was not possible because of the significant overlap in children's ages between studies (see <a href="#CD000060-tbl-0002">Table 1</a>) and reported data were not stratified by age group in individual studies. Total dose of treatment could not be reliably established as the majority of studies used nebulizer devices to deliver the drug. With such a wide age range of subjects it is unclear what proportion of the delivered dose reaches the child's airways (<a href="./references#CD000060-bbs2-0075" title="RubinBK , FinkJB . The delivery of inhaled medication to the young child. Pediatric Clinics of North America2003; Vol. 50, issue 3:717‐31. [0031‐3955: (Print)] ">Rubin 2003</a>), which would make any comparison difficult to interpret reliably. </p> </section> <section id="CD000060-sec-0084"> <h4 class="title">Secondary outcomes</h4> <p>Wide ranges of physiological and spirometric parameters were reported among the studies. However, such was the range of parameters used by different studies that the amount of data that could be pooled were limited. </p> <p>Statistically significant group differences favoring anticholinergic use were observed for lung function whether reported as 'change in % predicted FEV<sub>1</sub>' or as '% change in FEV<sub>1</sub>', clinical score at 120 minutes, oxygen saturation at 60 minutes and the need for repeat use of bronchodilators prior to discharge from the emergency department. No significant group difference was seen for the relapse rate. </p> </section> <section id="CD000060-sec-0085"> <h4 class="title">Adverse events</h4> <p>The combination of anticholinergics and SABAs was associated with a statistically significant 30% and 39% reduced risk of nausea and tremor, respectively. No significant group difference in vomiting was observed. Clinically important adverse effects, such as tachycardia or hypertension, were reported too infrequently to permit aggregation. Thus, the addition of anticholinergics to SABAs decreased the incidence of commonly observed beta<sub>2</sub>‐adrenergic effects in children treated with SABAs only. </p> </section> </section> <section id="CD000060-sec-0086"> <h3 class="title" id="CD000060-sec-0086">Overall completeness and applicability of evidence</h3> <p>The age range of subjects in the included studies ranged from four months to 18 years (with eight studies including preschool‐aged children). The diagnosis of asthma in young children represents a considerable challenge to clinicians and wheezy symptoms in children younger than 12 months may represent a different disease process (such as bronchiolitis) to asthma. The inclusion of studies with infants less than 12 months of age was carefully considered for its potential to confound the results. In the studies that included subjects less than 18 months of age (<a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a>; <a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a>; <a href="./references#CD000060-bbs2-0011" title="PhanichyakamP , KraisarinC , SasisakulpornC . Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pacific Journal of Allergy and Immunology1990;8:45‐8. ">Phanichyakam 1990</a>), the population age range was examined and in each case less than 5% of the population were under 18 months. With such a degree of homogeneity within the studies, the impact, if any, on the overall review was therefore likely to have been very small. Sensitivity analysis removing the only study (<a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a>) that reported admission data of the three studies that included children less than one year of age, did not alter the direction or magnitude of effect for the primary outcome (RR 0.74; 95% CI 0.63 to 0.86). </p> <p>With over half of the studies in this review being carried out in North America, the validity of study results to other countries should be considered. Large geographical variations in hospital admission rates have been predominantly attributed to differences in asthma diagnosis, use of daily prophylaxis, intensity of emergency therapy, admission criteria and bed availabilities (<a href="./references#CD000060-bbs2-0068" title="HomerCJ , SzilagyiP , RodewaldL , BloomSR , GreenspanP , YazdgerdiS , et al. Does quality of care affect rates of hospitalization for childhood asthma?. Pediatrics1996;98:18‐23. ">Homer 1996</a>; <a href="./references#CD000060-bbs2-0071" title="PayneSM , DonahueC , RappoP , McNamaraJJ , BassJ , FirstL , et al. Variations in pediatric pneumonia and bronchitis/asthma admission rates. Is appropriateness a factor?. Archives of Pediatric and Adolescent Medicine1995;149:162‐9. ">Payne 1995</a>). It is acknowledged in the UK and elsewhere, that admission rates in chronic disease may also be influenced by factors such as population deprivation and availability of primary care services (<a href="./references#CD000060-bbs2-0076" title="SaxenaS , GeorgeJ , BarberJ , FitzpatrickJ , MajeedA . Association of population and practice factors with potentially avoidable admissions rates for chronic diseases in London: cross sectional analysis. Journal of the Royal Society of Medicine2006;99(2):81‐9. ">Saxena 2006</a>). These factors may limit the external validity (generalizability) of study results, but as they would be applied similarly to both the treatment and control group within each study, this would not affect the internal validity of the observed effect. Interestingly, the absence of statistical heterogeneity of study results across trials provides reassurance to the robustness of study results across countries from which these studies originated. </p> </section> <section id="CD000060-sec-0087"> <h3 class="title" id="CD000060-sec-0087">Quality of the evidence</h3> <p>Like all systematic reviews, this meta‐analysis is limited by the quality of existing data (<a href="./references#CD000060-bbs2-0069" title="KhanKS , DayaS , JahadAR . The importance of quality of primary studies in producing unbiased systematic reviews. Archives of Internal Medicine1996;156:661‐6. ">Khan 1996</a>). This review examined studies for bias against fixed pre‐established criteria in keeping with current Cochrane review methodology. Potential biases were identified in five out of the 19 studies contributing data to our primary outcome. However, there were a far greater number of studies where the potential for bias was unclear. This could be a reflection of poor methodological reporting or poor methodology. Sensitivity analysis removing studies with potential bias did not change the direction and significance of the results for the primary outcome in any of the treatment protocols (<a href="./references#CD000060-bbs2-0001" title="BeckR . Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience [in French] [Utilisation du bromure d'ipratropium par voie inhalée pour le traitement de l'asthme aigu chez l'enfant]. Archives de Pediatrie1995;2 Suppl(2):145‐8. BeckR , RobertsonC , Galdes‐SebaldtM , LevisonH . Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. Journal of Pediatrics1985;107:605‐8. ">Beck 1985</a>; <a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a>; <a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a>; <a href="./references#CD000060-bbs2-0011" title="PhanichyakamP , KraisarinC , SasisakulpornC . Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pacific Journal of Allergy and Immunology1990;8:45‐8. ">Phanichyakam 1990</a>; <a href="./references#CD000060-bbs2-0020" title="SharmaA , MadaanA . Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian Journal of Pediatrics2004;71(2):121‐4. ">Sharma 2004</a>). Data from two unpublished studies (<a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a>; <a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a>) were included in this review and sensitivity analysis showed that removing them from the analysis did not impact significantly on the overall result for the primary outcome. </p> <p>Although only one study clearly described the physician making the decision to admit as blinded to the study medication, the double‐blinded nature of nearly all trials (18 out of 20 were double blinded) would imply that study physicians making such clinical decisions were also blinded to the study medication. This should be clearly reported in future trials. </p> <p>Despite these possible limitations, we did not consider them to have affected the strength or direction of the results for our primary outcome and so we rated the quality of evidence for the effect on hospital admission as high. However, unanswered questions remain regarding the optimal dose, intensity of therapy and severity of asthma exacerbations in relation to the reduced risk of hospital admission. </p> </section> <section id="CD000060-sec-0088"> <h3 class="title" id="CD000060-sec-0088">Potential biases in the review process</h3> <p>We attempted to minimize selection bias in the review process by using a broad search strategy and having the extracted data checked by a member of the editorial base of the Cochrane Airways Group. </p> </section> <section id="CD000060-sec-0089"> <h3 class="title" id="CD000060-sec-0089">Agreements and disagreements with other studies or reviews</h3> <p>The present review summarizes the best evidence available to April 2012. The first update identified three new trials not included in the first version of this review published in 1997. This update has added seven new trials. The conclusion regarding the single‐dose protocol and the multiple dose‐fixed protocol with regard the primary outcome remains unchanged due to the absence of new trials. With four additional trials in the multiple dose‐fixed protocol, the findings of the previous review were confirmed and strengthened. Thus supporting the addition of multiple doses of anticholinergics to SABAs for reducing hospital admission and improving lung function in children not only with severe but also with moderate asthma exacerbations. </p> <p>The findings of this review are similar to other reviews examining a paediatric population (<a href="./references#CD000060-bbs2-0073" title="RodrigoG , Castro‐RodriguezJ . Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta analysis. Thorax2005;60:740‐6. ">Rodrigo 2005</a><i>).</i> In their review, Rodrigo et al included 16 studies examining the use of anticholinergics plus SABAs versus SABAs alone in childhood asthma. Of those studies, 15 were examined in this review. <a href="./references#CD000060-bbs2-0053" title="TimsitS , SannierN , BocquetN , CojocaruB , WilleC , BoursiquotC , et al. Benefit of ipratropium bromide for the treatment of childhood asthma in the emergency department. Archives de Pediatrie2002;9(2):117‐24. ">Timsit 2002</a> was excluded from this review as the protocol examined a different dose of SABA in each treatment arm. The review concluded that "the addition of multiple doses of inhaled ipratropium bromide to SABAs is indicated in the standard treatment in children, adolescents and adults with moderate to severe exacerbations of asthma in the emergency setting" (<a href="./references#CD000060-bbs2-0073" title="RodrigoG , Castro‐RodriguezJ . Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta analysis. Thorax2005;60:740‐6. ">Rodrigo 2005</a>). In line with our definition, <a href="./references#CD000060-bbs2-0073" title="RodrigoG , Castro‐RodriguezJ . Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta analysis. Thorax2005;60:740‐6. ">Rodrigo 2005</a> defined severity by baseline spirometric testing (FEV<sub>1</sub> or peak expiratory flow (PEF) 50% to 70% of predicted as moderate exacerbation and FEV<sub>1</sub> or PEF less than 50% of predicted as a severe exacerbation or different clinical scores). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD000060-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgments about each methodological quality item for each included study." data-id="CD000060-fig-0001" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgments about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 1 Anticholinergic and short‐acting beta2‐agonists versus short‐acting beta2‐agonists alone (all protocols), outcome: 1.1 Primary outcome: hospital admissions." data-id="CD000060-fig-0002" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Forest plot of comparison: 1 Anticholinergic and short‐acting beta<sub>2</sub>‐agonists versus short‐acting beta<sub>2</sub>‐agonists alone (all protocols), outcome: 1.1 Primary outcome: hospital admissions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="In the children on short‐acting beta2‐agonists only, 23 people out of 100 were admitted to hospital, compared with 17 (95% CI 15 to 20) out of 100 for children on short‐acting beta2‐agonists plus anticholinergics." data-id="CD000060-fig-0003" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>In the children on short‐acting beta<sub>2</sub>‐agonists only, 23 people out of 100 were admitted to hospital, compared with 17 (95% CI 15 to 20) out of 100 for children on short‐acting beta<sub>2</sub>‐agonists plus anticholinergics. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of analysis 1.1." data-id="CD000060-fig-0004" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Funnel plot of analysis 1.1.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 1 Primary outcome: hospital admissions." data-id="CD000060-fig-0005" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 1 Primary outcome: hospital admissions. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 2 Primary outcome: hospital admissions subgrouped by trial protocol." data-id="CD000060-fig-0006" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 2 Primary outcome: hospital admissions subgrouped by trial protocol. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 3 Primary outcome: hospital admissions subgrouped by review authors' judgment of trial report." data-id="CD000060-fig-0007" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 3 Primary outcome: hospital admissions subgrouped by review authors' judgment of trial report. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 4 Primary outcome: hospital admissions subgrouped by control group event rate (tertiles)." data-id="CD000060-fig-0008" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 4 Primary outcome: hospital admissions subgrouped by control group event rate (tertiles). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 5 Primary outcome: hospital admissions subgrouped by co‐intervention of corticosteroid." data-id="CD000060-fig-0009" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 5 Primary outcome: hospital admissions subgrouped by co‐intervention of corticosteroid. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 6 Change from baseline in % predicted FEV1, 60 minutes after the last of IB." data-id="CD000060-fig-0010" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 6 Change from baseline in % predicted FEV<sub>1</sub>, 60 minutes after the last of IB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 7 Change from baseline in % predicted FEV1, 120 minutes after last IB." data-id="CD000060-fig-0011" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 7 Change from baseline in % predicted FEV<sub>1</sub>, 120 minutes after last IB. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 8 % Change in FEV1 or PEFR at 60 minutes after last IB (± 15 minutes)." data-id="CD000060-fig-0012" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 8 % Change in FEV<sub>1</sub> or PEFR at 60 minutes after last IB (± 15 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 9 % Change in FEV1 or PEFR at 120 minutes after last IB (± 30 minutes)." data-id="CD000060-fig-0013" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 9 % Change in FEV<sub>1</sub> or PEFR at 120 minutes after last IB (± 30 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 10 % Change in respiratory resistance at 60 minutes after IB (± 15 minutes)." data-id="CD000060-fig-0014" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 10 % Change in respiratory resistance at 60 minutes after IB (± 15 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 11 % Change in respiratory resistance at 120 minutes after IB (± 30 minutes)." data-id="CD000060-fig-0015" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 11 % Change in respiratory resistance at 120 minutes after IB (± 30 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 12 Change in clinical score at 120 minutes (± 30 minutes)." data-id="CD000060-fig-0016" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 12 Change in clinical score at 120 minutes (± 30 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 13 Need for repeat bronchodilator treatment after standard protocol prior to disposition." data-id="CD000060-fig-0017" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 13 Need for repeat bronchodilator treatment after standard protocol prior to disposition. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 14 O2 saturation &lt; 95% at 60 minutes (± 15 minutes)." data-id="CD000060-fig-0018" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 14 O<sub>2</sub> saturation &lt; 95% at 60 minutes (± 15 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 15 O2 saturation &lt; 95% at 120 minutes (± 30 minutes)." data-id="CD000060-fig-0019" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 15 O<sub>2</sub> saturation &lt; 95% at 120 minutes (± 30 minutes). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 16 Need for corticosteroids in emergency department prior to disposition." data-id="CD000060-fig-0020" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 16 Need for corticosteroids in emergency department prior to disposition. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 17 Tremor." data-id="CD000060-fig-0021" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 17 Tremor. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 18 Vomiting." data-id="CD000060-fig-0022" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 18 Vomiting. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 19 Nausea." data-id="CD000060-fig-0023" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 19 Nausea. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD000060-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/urn:x-wiley:14651858:media:CD000060:CD000060-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_t/tCD000060-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols), Outcome 20 Relapse." data-id="CD000060-fig-0024" src="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Anticholinergic and beta<sub>2</sub>‐agonists versus beta<sub>2</sub>‐agonists alone (all protocols), Outcome 20 Relapse. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/media/CDSR/CD000060/image_n/nCD000060-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD000060-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anticholinergic and short‐acting beta2‐agonists versus beta2‐agonists alone (all protocols) for initial treatment of acute asthma in children</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Anticholinergic and shorth‐acting beta<sub>2</sub>‐agonists (SABA) versus SABA alone (all protocols) for initial treatment of acute asthma in children</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> children with initial treatment of acute asthma<br/> <b>Settings:</b> emergency department<br/> <b>Intervention:</b> anticholinergic and SABA versus SABA alone (all protocols) </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Anticholinergic and SABA versus SABA alone (all protocols)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary outcome: hospital admissions</b> <br/> hospital admissions </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>23 per 100</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>17 per 100</b> <br/> (15 to 20) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.73</b> <br/> (0.63 to 0.85) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2497<br/> (19 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 studies had no admissions so did not contribute to the RR.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> is the mean control group risk across studies. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>RR:</b> risk ratio; <b>SABA:</b> short‐acting beta‐agonists. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Anticholinergic and short‐acting beta2‐agonists versus beta2‐agonists alone (all protocols) for initial treatment of acute asthma in children</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000060-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study treatments</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Age range (years)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Delivery device</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose of ipratropium bromide</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of doses</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Total dose delivered</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="6" valign=""> <p><b>Single dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0001" title="BeckR . Use of ipratropium bromide by inhalation in the treatment of acute asthma in children. Clinical experience [in French] [Utilisation du bromure d'ipratropium par voie inhalée pour le traitement de l'asthme aigu chez l'enfant]. Archives de Pediatrie1995;2 Suppl(2):145‐8. BeckR , RobertsonC , Galdes‐SebaldtM , LevisonH . Combined salbutamol and ipratropium bromide by inhalation in the treatment of severe acute asthma. Journal of Pediatrics1985;107:605‐8. ">Beck 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐17.5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MDI and spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0006" title="CookJJ , FergussonDM , DawsonKP . Ipratropium and fenoterol in the treatment of acute asthma. Pharmatherapeutica1985;4(6):383‐6. ">Cook 1985</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐2 mL of 0.025% solution</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐2 mL of 0.025% solution</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0011" title="PhanichyakamP , KraisarinC , SasisakulpornC . Comparison of inhaled terbutaline and inhaled terbutaline plus ipratropium bromide in acute asthmatic children. Asian Pacific Journal of Allergy and Immunology1990;8:45‐8. ">Phanichyakam 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MDI and spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0019" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (single)</a> (single dose) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="16" valign=""> <p><b>Multiple fixed‐dose protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 months to 16 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0009" title="IramainR , Lopez‐HerceJ , CoronelJ , SpittersC , GuggiariJ , BogadoN . inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. Journal of Asthma2011;48:298‐303. ">Iramain 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg children over 20 kg</p> <p>250 mcg children under 20 kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3000 mcg or 1500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0014" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998 (moderate)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0015" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐35. ">Qureshi 1998 (severe)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0016" title="ReismanJ , Galdes‐SebaldtM , KazimF , CannyG , LevisonH . Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. Journal of Allergy &amp; Clinical Immunology1988;81:16‐20. ">Reisman 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0017" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995</a> (multiple dose) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0020" title="SharmaA , MadaanA . Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian Journal of Pediatrics2004;71(2):121‐4. ">Sharma 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0021" title="Sienra MongeJJ , Bermejo GuevaraMA , delRio NavarroBE , Rosas VargasMA , Reyes RuizNI . Degree and duration of bronchodilatation with an agonist beta 2 administered alone versus an agonist beta 2 administered with ipratropium bromide in children with acute asthma. Revista Alergia Mexico2000;47(1):26‐9. ">Sienra Monge 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MDI and spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>120 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>240 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0022" title="WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children [Abstract]. Chest2004;126(4 Suppl):761S‐b. WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. Annals of Allergy, Asthma, &amp; Immunology2006;96(5):701‐6. ">Watanasomsiri 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>750 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0023" title="WatsonWTA , BeckerAB , SimmonsFER . Comparison of ipratropium solution, fenoterol solution and their combination administered by nebulizer and face mask to children with acute asthma. Journal of Allergy &amp; Clinical Immunology1988;82:1012‐8. ">Watson 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0025" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (mild)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0026" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (moderate)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0027" title="ZorcJJ , Pusic , MV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (severe)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1‐17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>500 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1000 mcg</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Multiple</b> flexible‐<b>dose protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0004" title="CalvoGM , CalvoAM , MarinHF , MoyaGJ . Is it useful to add an anticholinergic treatment to beta2‐adrenergic medication in acute asthma attack. Journal of Investigative Allergology Clinical Immunology1998;8(1):30‐4. ">Calvo 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5‐14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MDI and spacer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20 mcg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Max 7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140 mcg (max)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0008" title="GuillMF , MaloneyMJ , DuRantRH . Comparison of inhaled metaproterenol, inhaled atropine sulfate and their combination in treatment of children with acute asthma. Annals of Allergy1987;59:367‐71. ">Guill 1987</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 months to 13 years</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Nebulized</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.05‐0.1 mg/kg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Max 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.15‐0.3 mg/kg (max)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>Max: maximum; MDI: metered‐dose inhaler.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study treatments</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000060-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Severity based on review author assessment of trial report</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MEAN FEV<sub>1</sub>/PEFR (inclusion criteria)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> MEAN score</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Trial report description of severity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Review authors severity classification</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Age</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Beck 1995</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV 30‐31% (eligibility: FEV<sub>1</sub> &lt; 50% pred) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 years‐upper range not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Benito‐Fernandez 2000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean PEF: 45% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 on a 5‐point score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 months to 16 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>BI (pers comm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear if measured</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>severity score of 13 (unknown scale)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐10 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Calvo (1998)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEF = 69‐71% (excluded if PEF &gt; 80% pred.)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐point TAL score: 5.6‐6 (moderate)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐14 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chakraborti (2006)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> 69‐71 ± 37% (S+IB) and 57 ± 21% (S alone) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10‐point clinical asthma score 1.83 (S+IB) vs. 2.07 (S alone)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and moderate  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐15 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Ducharme (1998)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Children requiring continuous nebulizations of salbutamol were excluded</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild and moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mild and moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐7 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Iramain (2011)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> 60‐64%/PEF 62‐60% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15‐point pulmonary score: 12.3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐18 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pederson (1996)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean not reported (eligibility FEV<sub>1</sub> &lt; 70% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐12 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qureshi (1997)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> and PEF at baseline 37% and 34% (eligibility FEV<sub>1</sub> &lt; 50% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐18 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qureshi (1998) (sev)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup data provided by author:</p> <p>FEV<sub>1</sub> 34% (eligibility FEV<sub>1</sub> &lt; 50% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12‐15 on 15‐point asthma score)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐18 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Qureshi (1998) (mod)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroup data provided by author:</p> <p>FEV<sub>1</sub> 55% (eligibility: 50% &lt; FEV<sub>1</sub> &lt; 70% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐11 on a 15‐point Clinical score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2‐18 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reisman (1998)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub> 33‐40% (eligibility; FEV<sub>1</sub> &lt; 55% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐15 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Schuh (1995)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>mean FEV<sub>1</sub>‐34% (eligibility; FEV<sub>1</sub> &lt; 50% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>wheezing score 2.2‐2.5 on max of 3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5‐17 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sharma (2004)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>PEF 35% pred. (excluded PEF &lt; 30% pred. and signs of impending respiratory disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Wheezing score 2.5 to 2.6 (max = 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐14 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sienra monge (2000)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FEV<sub>1</sub>: 1 L </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unrated</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8‐15 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Watson (1988)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean FEV<sub>1</sub> not reported (eligibility FEV<sub>1</sub>: 30‐70% pred.) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7‐6 on a scale of 0 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6‐17 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Watanasomsiri (2006)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean % pred. PEFR at baseline 27‐30% in the subset of people cooperating with the forced expiratory technique)(PEFR was not an inclusion criteria) no exclusion or inclusion based on severity </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.42 on a scale of 0 to 12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Proportion of moderate asthma: 73% and of severe asthma: 27%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate and severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3‐15 years</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Zorc (1999)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Subgroups data obtained from authors</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 strata (mild, moderate and severe)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1‐17 years</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>FEV<sub>1</sub>: forced expiratory volume in one second; IB: ipratropium bromide; max: maximum; PEF: peak expiratory flow; PEFR: peak expiratory flow rate; pred.: predicted; S: salbutamol; y.o.: years old. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Severity based on review author assessment of trial report</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000060-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Studies grouped by control group event rate as a proxy for severity</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Admission rate</b> </p> <p><b>(control group)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline population spirometry characteristics</b> </p> <p><b>(where available)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Admission rate ‐ ranking</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="15" valign=""> <p><b>Multiple fixed‐dose protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0002" title="Benito FernandezJ , Mintegui RasoS , Sanchez EchanizJ , Vazquez RoncoMA , Pijoan ZubizarretaJI . Efficacy of early administration of nebulized ipratropium bromide in children with asthmatic crisis [in Spanish]. Anales Espanoles de Pediatria2000;53(3):217‐22. ">Benito Fernandez 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEFR (%) mean 44.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0015" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐35. ">Qureshi 1998 (severe)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEFR &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0018" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (multiple)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 50% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0012" title="QureshiFA , ZaritskyA , LakkisH . Efficacy of nebulized ipratropium in severe asthmatic children. Annals of Emergency Medicine1997;29:205‐11. ">Qureshi 1997</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEFR &lt; 50% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0009" title="IramainR , Lopez‐HerceJ , CoronelJ , SpittersC , GuggiariJ , BogadoN . inhaled salbutamol plus ipratropium in moderate and severe asthma crises in children. Journal of Asthma2011;48:298‐303. ">Iramain 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.43</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEF or FEV<sub>1</sub> &lt; 60% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0027" title="ZorcJJ , Pusic , MV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (severe)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.41</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0010" title="PetersonR , WensleyD , MitchellI , KlassenT , LamarreJ , RivardG , et al. Boehringer Ingelheim Trial No 2442430.3. Boehringer Ingelheim1994. ">Peterson 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 70% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0026" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (moderate)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0016" title="ReismanJ , Galdes‐SebaldtM , KazimF , CannyG , LevisonH . Frequent administration by inhalation of salbutamol and ipratropium bromide in the initial management of severe acute asthma in children. Journal of Allergy &amp; Clinical Immunology1988;81:16‐20. ">Reisman 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 55% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0020" title="SharmaA , MadaanA . Nebulized salbutamol vs salbutamol and ipratropium combination in asthma. Indian Journal of Pediatrics2004;71(2):121‐4. ">Sharma 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% predicted PEFR 34.4% (mean)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0014" title="QureshiF , PestianJ , DavisP , ZaritskyA . Effect of nebulized ipratropium on the hospitalization rates of children with asthma. New England Journal of Medicine1998;339(15):1030‐5. ">Qureshi 1998 (moderate)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PEFR &lt; 70% predicted</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0022" title="WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol versus salbutamol alone in acute asthma exacerbation in children [Abstract]. Chest2004;126(4 Suppl):761S‐b. WatanasomsiriA , PhipatanakulW . Comparison of nebulized ipratropium bromide with salbutamol vs salbutamol alone in acute asthma exacerbation in children. Annals of Allergy, Asthma, &amp; Immunology2006;96(5):701‐6. ">Watanasomsiri 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>% PEFR 29.2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0003" title="Boehringer IngelheimPharmaceuticals . A comparison of Combivent UDV (ipratropium 500mcg and salbutamol 2.5mg) and salbutamol UDV alone (2.5mg). Personal communication from Boehringer Ingelheim2009. ">BI [pers comm]</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.09</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0025" title="ZorcJJ , PusicMV , OgbornCJ , LebetR , DugganAK . Ipratropium bromide added to asthma treatment in the pediatric emergency department. Pediatrics1999;103(4):748‐52. ">Zorc 1999 (mild)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.07</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0023" title="WatsonWTA , BeckerAB , SimmonsFER . Comparison of ipratropium solution, fenoterol solution and their combination administered by nebulizer and face mask to children with acute asthma. Journal of Allergy &amp; Clinical Immunology1988;82:1012‐8. ">Watson 1988</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign=""> <p><b>Single‐dose protocol</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0019" title="SchuhS , JohnsonDW , CallahanS , CannyG , LevisonH . Efficacy of frequent nebulized ipratropium added to frequent high‐dose albuterol therapy in severe childhood asthma. Journal of Pediatrics1995;126:639‐45. ">Schuh 1995 (single)</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 50% predicted </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0007" title="DucharmeFM , DavisGM . Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the treatment of mild and moderate acute asthma. Journal of Pediatrics1998;133(4):479‐85. ">Ducharme 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Respiratory resistance</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD000060-bbs2-0005" title="ChakrabortiA , LodhaR , PandeyRM , KabraSK . Randomized controlled trial of ipratropium bromide and salbutamol versus salbutamol alone in children with acute exacerbation of asthma. Indian Journal of Pediatrics.2006;73(11):979‐83. ">Chakraborti 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.00</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FEV<sub>1</sub> &lt; 80% </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>FEV<sub>1</sub>: forced expiratory volume in one second; PEF: peak expiratory flow; PEFR: peak expiratory flow rate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Studies grouped by control group event rate as a proxy for severity</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD000060-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Number needed to treat for hospital admissions grouped by severity tertile</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk tertile</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Weighted control group risk</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Risk ratio (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Corresponding treatment group risk (95% CI)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NNTB (95% CI)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.91 (0.59 to 1.42)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7% (4 to 11)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>139 (not significant)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24.1%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.75 (0.57 to 0.99)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18% (14 to 24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (10 to 415)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48.7%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0.68 (0.56 to 0.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33% (27 to 40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7 (5 to 12)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>Comparing the control group weighted risk against the treatment group's risk it can be seen that the NNTB in the high risk group was 7 versus 13 in the medium‐risk group and 131 in the low‐risk group. </p> <p>CI: confidence interval; NNTB: number need to treat for an additional beneficial effect.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Number needed to treat for hospital admissions grouped by severity tertile</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/full#CD000060-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD000060-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: hospital admissions <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Primary outcome: hospital admissions subgrouped by trial protocol <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Single‐dose protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>419</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.56, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Multiple fixed‐dose protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1998</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.72 [0.61, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Multiple flexible‐dose protocol</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Primary outcome: hospital admissions subgrouped by review authors' judgment of trial report <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2497</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1188</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.61, 0.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Moderate‐severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.41, 0.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.49, 1.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.4 Mild‐moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>358</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.52, 1.47]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.5 Mild</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.43 [0.42, 4.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Primary outcome: hospital admissions subgrouped by control group event rate (tertiles) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2417</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 High control group event rate (upper tertile)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>669</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.56, 0.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Medium control group event rate (middle tertile)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>780</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.57, 0.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Low control group event rate (lower tertile)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>968</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.59, 1.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Primary outcome: hospital admissions subgrouped by co‐intervention of corticosteroid <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2407</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.63, 0.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Background corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1043</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.59, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 No background corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.47, 0.94]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.3 Variable (at physicians discretion)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.54, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.4 Not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>500</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.48, 1.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Change from baseline in % predicted FEV<sub>1</sub>, 60 minutes after the last of IB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>402</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>10.08 [6.24, 13.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Change from baseline in % predicted FEV<sub>1</sub>, 120 minutes after last IB <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.87 [1.17, 12.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 % Change in FEV<sub>1</sub> or PEFR at 60 minutes after last IB (± 15 minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.25, 0.88]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 % Change in FEV<sub>1</sub> or PEFR at 120 minutes after last IB (± 30 minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>219</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.12 [‐0.15, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 % Change in respiratory resistance at 60 minutes after IB (± 15 minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>294</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.02, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Co‐intervention: corticosteroids during the previous 60 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>70</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.13, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2 Co‐intervention: no corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>224</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.02, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 % Change in respiratory resistance at 120 minutes after IB (± 30 minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.09, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Co‐intervention: corticosteroids during the previous 120 minutes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.12, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.2 Co‐intervention: no corticosteroids</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.12, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Change in clinical score at 120 minutes (± 30 minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.23 [‐0.42, ‐0.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Need for repeat bronchodilator treatment after standard protocol prior to disposition <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1074</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.79, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 O<sub>2</sub> saturation &lt; 95% at 60 minutes (± 15 minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>416</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.55, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 O<sub>2</sub> saturation &lt; 95% at 120 minutes (± 30 minutes) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>185</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.10 [0.76, 1.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Need for corticosteroids in emergency department prior to disposition <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.73, 1.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Tremor <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>524</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.69 [0.51, 0.93]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Vomiting <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.88 [0.49, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Nausea <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>757</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.38, 0.95]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Relapse <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1389</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [0.68, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Anticholinergic and beta2‐agonists versus beta2‐agonists alone (all protocols)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD000060.pub2/references#CD000060-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD000060.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD000060-note-0003">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD000060-note-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD000060-note-0002">Français</a> </li> <li class="section-language"> <a class="" href="ru#CD000060-note-0001">Русский</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000060\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000060\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000060\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD000060\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD000060\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=4nUWI3Cc&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000060.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD000060.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD000060.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD000060.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD000060.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718053256"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000060.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718053260"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD000060.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dc6f1981af49c',t:'MTc0MDcxODA1My4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 